FMRI评价补肾法为主促进MS神经损伤修复机制研究
|
摘要
目的
通过检测复发缓解型多发性硬化(Relapsing-Remitting Multiple Sclerosis, RRMS)患者的质子共振波谱分析与弥散张量成像指标,研究并探讨中医补肾法对多发性硬化的髓鞘再生与轴索修复的作用,及其与西药治疗的差异,为中医辨证论治提供临床科学证据。
材料与方法
1.病例来源及分组
入组患者均为2012年9月至2014年1月的就诊于首都医科大学附属北京天坛医院中医科门诊及神经内科门诊病人,并设立健康对照组。临床确诊RRMS患者56例,其中中医科门诊患者40例为中医治疗组,神经内科门诊病例16例为西药治疗组,健康人11例为健康对照组。参照中医辨证分类标准,中医治疗组分为肾虚型和其他证型,其中肾虚型患者29例,为补肾治疗组,其他证型11例,为其他证型治疗组。西药治疗组均为肾虚型。
2.治疗方法与观察指标
(1)治疗方法补肾治疗组肝肾阴虚型予二黄方治疗,脾肾阳虚型与二黄方加附子等治疗；其他证型治疗组主要分为气虚痰瘀型及痰热瘀阻型,依据不同证型给予相应辨证治疗：气虚痰瘀型予黄芪桂枝五物汤,痰热瘀阻型予黄连温胆汤合桃红四物汤治疗；西药治疗组予西医常规治疗。
(2)观察指标及随访周期入组时详细记录各组患者一般资料,包括发病年龄、病程长短、复发次数、中医临床症状分布、神经系统症状分布,进行扩展伤残等级评分(Expended Disability Score Standard, EDSS)及中医症状评分。同时各组患者及健康对照组行头颅核磁检查,记录各组患者及健康对照组核磁质子共振波谱分析(MR Spectroscopy, MRS)及弥散张量成像(Diffusion Tensor Imaging, DTI)。MRS主要检测指标包括：N-乙酰天门冬氨酸(N-acetylaspartate,Naa1、胆碱(Choline,Cho)、总肌酸(Creatine,Cr),藉由病灶侧及正常侧Naa/Cr、Cho/Cr作为评价标准。DTI主要检测指标包括：表观弥散系数(Apparent Diffusion Coefficient, ADC)及各向异性(Fractional Anisotropy, FA)。随访周期为9个月,随访结束时三组RRMS患者再次记录中医及神经症状分布,进行扩展伤残等级评分(Expended Disability Score Standard, EDSS).中医症状评分,及头颅核磁检查,指标同前。
第一部分：观察治疗前补肾治疗组、西药治疗组中医临床症状分布、神经系统症状分布、EDSS评分、中医症状评分的差异,及两组MRS、DTI指标与健康对照组差异,并比较治疗前后补肾治疗组、西药治疗组EDSS评分、中医症状评分、MRS、DTI指标变化。
第二部分：观察治疗前补肾治疗组、其他证型治疗组中医临床症状分布、神经系统症状分布、EDSS评分、中医症状评分的差异,及两组MRS、DTI指标与健康对照组差异,并比较治疗前后补肾治疗组、其他证型治疗组EDSS评分、中医症状评分、MRS、 DTI指标变化。
结果
第一部分FMRI评价补肾为主及西药治疗促进MS神经损伤修复作用的差异
1.中医临床症状分布治疗前：补肾治疗组与西药治疗组患者在中医临床症状分布无显著差异,P>0.05。治疗后：补肾治疗组在身痛、肢体无力、跟跖疼痛、四肢发麻、头晕、头痛、视力模糊、不寐、多梦、小便频急、健忘、急躁易怒及潮热盗汗等例数显著低于西药治疗组,P<0.05,提示补肾治疗组中医临床症状显著缓解。
2.神经系统症状分布治疗前：补肾治疗组与西药治疗组患者在神经系统症状分布无显著差异,P>0.05。治疗后：补肾治疗组在肢体无力、感觉障碍、视力障碍、小便功能障碍、共济失调、大脑皮层功能减退及发作性症状等例数显著低于西药治疗组,P<0.05,提示补肾治疗组神经系统症状显著缓解。
3.EDSS评分及中医症状评分治疗前：补肾治疗组与西药治疗组患者EDSS评分、中医症状评分均无显著差异,P>0.05。治疗后：补肾治疗组EDSS评分、中医症状评分显著低于西药治疗组,P<0.05。两组患者治疗后的EDSS评分及中医症状评分较治疗前均有所下降,而补肾治疗组下降程度更加显著,P<0.05,提示补肾治疗组神经系统功能修复较好。
4.质子共振波谱分析(MRS)治疗前：补肾治疗组及西药治疗组NAA/CR比值均显著低于健康对照组,而CHO/CR比值均显著高于健康对照组,P<0.05,提示两组的髓鞘脱失及轴索损伤显著。两组间无显著差异,P>0.05。治疗后：西药治疗组NAA/CR比值显著低于健康对照组,而CHO/CR比值显著高于健康对照组,P<0.05；补肾治疗组NAA/CR比值及CHO/CR比值均和健康对照组无差异,P>0.05；而其NAA/CR比值显著高于西药治疗组,CHO/CR比值显著低于西药治疗组,P<0.05。补肾治疗组NAA/CR比值上升及CHO/CR比值下降幅度均较西药治疗组显著,P<0.05。上述结果提示补肾治疗组髓鞘修复及轴索再生显著优于西药治疗组。
5.弥散张量成像分析(DTI)治疗前：补肾治疗组及西药治疗组ADC比值均显著高于健康对照组,而FA比值均显著低于健康对照组P<0.05,提示两组神经纤维束损伤显著。两组间无显著差异,P>0.05。治疗后：西药治疗组ADC比值显著高于健康对照组,而FA比值显著低于健康对照组,P<0.05；补肾治疗组ADC比值及FA比值均和健康对照组无差异,P>0.05；而其FA比值显著高于西药治疗组,ADC比值显著低于西药治疗组,P<0.05。补肾治疗组FA比值上升及ADC比值下降幅度均较西药治疗组显著,P<0.05。上述结果提示补肾治疗组神经纤维束修复显著优于西药治疗组。
第二部分FMRI评价中医辨证治疗促进不同证型MS神经损伤修复作用的差异
1.中医临床症状分布治疗前：补肾治疗组与其他证型治疗组患者在中医临床症状分布无显著差异,P>0.05。治疗后：补肾治疗组在筋脉拘挛、头晕、头痛及口干等例数显著低于其他证型治疗组,P<0.05,提示补肾治疗组中医临床症状缓解较佳。
2.神经系统症状分布治疗前：补肾治疗组与其他证型治疗组患者在神经系统症状分布无显著差异,P>0.05。治疗后：补肾治疗组在共济失调例数显著低于其他证型治疗组,P<0.05,提示补肾治疗组神经系统症状缓解较佳。
3EDSS评分及中医症状评分治疗前：补肾治疗组与其他证型治疗组患者EDSS评分、中医症状评分均无显著差异,P>0.05。治疗后：补肾治疗组EDSS及中医症状评分低于其他证型治疗组,但P>0.05,差异无统计学意义,提示补肾治疗组神经系统功能修复趋向较好。
4.质子共振波谱分析(MRS)治疗前：补肾治疗组及其他证型治疗组NAA/CR比值均显著低于健康对照组,而CHO/CR比值均显著高于健康对照组P<0.05,两治疗组间无显著差异,P>0.05。治疗后：其他证型治疗组NAA/CR比值略低于健康对照组,而CHO/CR比值略高于健康对照组,P>0.05；补肾治疗组NAA/CR比值及CHO/CR比值均和健康对照组无差异,P>0.05；而其NAA/CR比值高于其他证型治疗组,CHO/CR比值低于其他证型治疗组,但差异无统计学意义,P>0.05。上述结果提示补肾治疗组髓鞘修复及轴索再生趋向优于其他证型治疗组。
5.弥散张量成像分析(DTI)治疗前：补肾治疗组及其他证型治疗组ADC比值均显著高于健康对照组,而FA比值均显著低于健康对照组,P<0.05,两组间无显著差异,P>0.05。治疗后：其他证型治疗组ADC比值显著高于健康对照组,而FA比值显著低于健康对照组,P<0.05；补肾治疗组ADC比值及FA比值均和健康对照组无差异,P>0.05；而其ADC比值显著低于其他证型治疗组,FA比值显著高于其他证型治疗组,P<0.05。补肾治疗组ADC比值下降及FA比值上升幅度均较其他证型治疗组显著,P<0.05。上述结果提示补肾治疗组神经纤维束修复显著优于其他证型治疗组。
结论
1通过治疗前后比较,补肾治疗组中医临床症状及神经系统症状较西药治疗组及其他证型治疗组显著减少,提示补肾为主治疗MS能有效缓解临床症状。
2通过治疗前后比较,补肾治疗组EDSS及中医症状评分较西药治疗组显著下降,提示补肾为主治疗MS能有效修复神经系统功能。
3通过MRS检测治疗前后数据比较,补肾治疗组Naa/Cr比值较西药治疗组显著上升、Cho/Cr比值较西药治疗组显著下降,提示补肾治疗MS能有效促进髓鞘修复及轴索再生。
4通过DTI检测治疗前后数据比较,补肾治疗组ADC比值均较西药治疗组及其他证型治疗组显著下降、FA比值均较西药治疗组及其他证型治疗组显著上升,提示补肾治疗MS能有效促进神经纤维束修复。
Objective
Compared with the western medicine treatment effects, we research and confer repair and regeneration of myelin sheath, axon and nerve fiber of TCM tonifying the kidney treating the relapsing-remitting multiple sclerosis patients by detecting MR Spectroscopy and Diffusion Tensor Image to provide the TCM diagnosis theory scientific evidence.
Materials and Methods
1. Patient source and division
The experiment patients come from Sep.2012to Jan.2014Beijing Tiantan Hospital TCM and neurology department out-hospital patients. We establish the health control group. There are56diagnosed relapsing remitting multiple sclerosis(RRMS) patients, including40ones from TCM and16ones from the neurology departments. The health control group includes11healthy persons. According to the TCM diagnosis criteria, the TCM patients are divided into the kidney deficiency type and the other TCM types. The tonifying the kidney group includes29kidney deficiency type patients. The other TCM type treatment group includes11the other TCM type patients. The western medicine treatment group includes16kidney deficiency type patients.
2. Treatment and observed indexes
(1) Treatment The tonifying the kidney group patients are given Erhuang formula for Gan Shen yin deficiency ones and Erhuang formula adding Fuzi for Pi Shen yang deficiency ones. The other TCM type treatment group patients are divided into Qi deficiency phlegm stasis type and phlegm heat stasis type. The Qi deficiency phlegm stasis type patients are given Huangqi guizhi wu wu formula and the phlegm heat stasis type ones are given Huanglian wendan formula and Taohong siwu formula. The western medicine treatment patients are given the normal western medicine.
(2) Observed indexes and periods The patients are recorded the general data, including the age of first attack, disease duration, relapsing times, TCM clinic syndromes distribution, neurologic systematic syndromes distribution, Expended Disability Score Standard(EDSS) and TCM syndromes scores. The patients and health control group persons receive MRI detection and are recorded the lesion and normal sides data of MR Spectroscopy(MRS) and Diffusion Tensor Imaging(DTI) data. MRS data include N-acetylaspartate(Naa), Choline(Cho) and Creatine(Cr). The MRS observed indexes include Naa/Cr and Cho/Cr ratios of lesion and normal sides. The DTI observed indexes include Apparent Diffusion Coefficient(ADC) and Fractional Anisotropy(FA) of lesion and normal sides. The observing period is9months. After the continuous9months treatment, the three RRMS patients are recorded TCM and neurologic syndromes distribution. They are evaluated EDSS and TCM syndromes scores. They also receive MRI detection and the observed indexes are mentioned on the above.
Section1:Before treatment, the TCM clinic syndromes distribution, neurologic systematic syndromes distribution, EDSS and TCM syndromes scores difference is observed between the tonifying the kidney and western medicine treatment groups. The MRS and DTI observed indexes difference is compared among the two groups and the health control group. Before and after treatment, the tonifying the kidney and western medicine treatment groups' TCM and neurologic syndromes distribution, EDSS and TCM syndromes scores are compared. Besides, the two groups'MRS and DTI observed indexes changes are compared.
Second2:Before treatment, we observe the TCM clinic syndromes distribution, neurologic systematic syndromes distribution, EDSS and TCM syndromes scores of the tonifying the kidney and other TCM treatment groups. We compare the MRS and DTI indexes difference among the two groups and the health control group. Before and after treatment, we also compare the TCM and neurologic syndromes distribution, EDSS and TCM syndromes scores, MRS and DTI indexes changes between the the tonifying the kidney and other TCM treatment groups.
Results
Section1:FMRI estimate the nerve damage and repair difference between the tonifying the kidngy and western medicine treating MS patients
1. TCM syndromes distribution Before treatment, there is no distribution difference between the tonifying the kidney and western medicine treatment groups with P>0.05. After treatment, the tonifying the kidney group's number of patients complaining bodily pain, impotent limbs, heels irritation, limbs numbness, giddiness, cephalalgia, blurred vision, insomnia, dreamy rest, urgent urination, obliviousness, fidget, hectic fever and night sweat is obviously lowered than the western medicine treatment group's number with P<0.05. It shows the tonifying the kidney group's TCM syndromes get recovery remarkably.
2. Neurologic syndromes distribution Before treatment, there is no distribution difference between the tonifying the kidney and western medicine treatment groups with P>0.05. After treatment, the tonifying the kidney group's number of patients complaining impotent limbs, sensation paralysis, blurred vision, failed urination, ataxia, decreased cerebrum cortex function and relapsing syndromes is obviously lowered than the western medicine treatment group's number with P<0.05. It shows the tonifying the kidney group's neurologic syndromes get recovery remarkably.
3. EDSS and TCM syndromes scores Before treatment, there is no EDSS and TCM syndromes scores difference between the tonifying the kidney and western medicine treatment groups with P>0.05. After treatment, the tonifying the kidney group's EDSS and TCM syndromes scores are obviously lowered than those of the western medicine treatment group with P<0.05. The two groups'EDSS and TCM syndromes scores decrease after treatment. The tonifying the kidney group's EDSS and TCM syndromes scores decrease more obviously with P<0.05. It shows the tonifying the kidney group's neurologic function get recovery remarkably.
4. MR Spectroscopy(MRS) Before treatment, the tonifying the kidney and western medicine treatment groups'NAA/CR ratios are obviously lower and CHO/CR ratios are obviously higher than the ratios of the health control group with P<0.05. It shows the two groups'demyelination and axonal damage is obvious. There is no difference between the ratios of the two groups with P>0.05. After treatment, the western medicine treatment group's NAA/CR ratio is obviously lower than the ratio of the health control group. The western medicine treatment group's CHO/CR ratio is obviously higher than the ratio of the health control group with P<0.05. There is no difference between the two ratios of the tonifying the kidney group and the health control group with P>0.05. The tonifying the kidney group's NAA/CR ratio is obviously higher than the ratio of the western medicine treatment group. The tonifying the kidney group's CHO/CR ratio is obviously lower than the ratio of the western medicine treatment group with P<0.05. The tonifying the kidney group's NAA/CR ratio increasing and CHO/CR ratio decreasing margins are obviously wider than the margins of the western medicine treatment group with P<0.05. It shows the tonifying the kidney group's myelin sheath repair and axon regeneration is obviously better than that of the western medicine treatment group.
5. Diffusion Tensor Imaging(DTI) Before treatment, the tonifying the kidney and western medicine treatment groups'ADC ratios are obviously higher and CHO/CR ratios are obviously lower than the ratios of the health control group with P<0.05. It shows the two groups'nerve fiber damage is obvious. There is no difference between the ratios of the two groups with P>0.05. After treatment, the western medicine treatment group's ADC ratio is obviously higher than the ratio of the health control group. The western medicine treatment group's FA ratio is obviously lower than the ratio of the health control group with P<0.05. There is no difference between the two ratios of the tonifying the kidney group and the health control group with P>0.05. The tonifying the kidney group's FA ratio is obviously higher than the ratio of the western medicine treatment group. The tonifying the kidney group's ADC ratio is obviously lower than the ratio of the western medicine treatment group with P<0.05. The tonifying the kidney group's FA ratio increasing and ADC ratio decreasing margins are obviously wider than the margins of the western medicine treatment group with P<0.05. It shows the tonifying the kidney group's nerve fiber tract repair is obviously better than that of the western medicine treatment group.
Section2:FMRI estimate the nerve damage and repair difference between the different TCM types diagnosing and treating MS patients
1. TCM syndromes distribution Before treatment, there is no distribution difference between the tonifying the kidney and the other TCM treatment groups with P>0.05. After treatment, the tonifying the kidney group's number of patients complaining spasm, giddiness, cephalalgia and thirsty is obviously lowered than the other TCM treatment group's number with P<0.05. It shows the tonifying the kidney group's TCM syndromes get better recovery.
2. Neurologic syndromes distribution Before treatment, there is no distribution difference between the tonifying the kidney and other TCM treatment groups with P>0.05. After treatment, the tonifying the kidney group's number of patients complaining ataxia is obviously lowered than the other TCM treatment group's number with P<0.05. It shows the tonifying the kidney group's neurologic syndromes get better recovery.
3. EDSS and TCM syndromes scores Before treatment, there is no EDSS and TCM syndromes scores difference between the tonifying the kidney and other TCM treatment groups with P>0.05. After treatment, the tonifying the kidney group's EDSS and TCM syndromes scores tend to be lower than those of the other TCM treatment group with P>0.05. The tonifying the kidney group's EDSS and TCM syndromes scores decreasing margins tend to be wider than those of the other TCM treatment group. It shows the tonifying the kidney group's neurologic function tends to get better recovery.
4. MR Spectroscopy(MRS) Before treatment, the tonifying the kidney and other TCM treatment groups'NAA/CR ratios are obviously lower and CHO/CR ratios are obviously higher than the ratios of the health control group with P<0.05. It shows the two groups' demyelination and axonal damage is obvious. There is no difference between the ratios of the two groups with P>0.05. There is no difference among the two ratios of the tonifying the kidney, TCM treatment and the health control groups after treatment with P>0.05. The tonifying the kidney group's NAA/CR ratio tends to be higher than the ratio of the other TCM treatment groups. The tonifying the kidney group's CHO/CR ratio tends to be lower than the ratio of the other TCM treatment group with P<0.05. The tonifying the kidney group's NAA/CR ratio increasing and CHO/CR ratio decreasing margins tend to be wider than the margins of the other TCM treatment group with P>0.05. It shows the tonifying the kidney group's myelin sheath repair and axon regeneration tends to be better than that of the other TCM treatment group.
5. Diffusion Tensor Imaging(DTI) Before treatment, the tonifying the kidney and other TCM treatment groups'ADC ratios are obviously higher and FA ratios are obviously lower than the ratios of the health control group with P<0.05. There is no difference between the ratios of the two groups with P>0.05. After treatment, the other TCM treatment group's ADC ratio is obviously higher than the ratio of the health control group. The other TCM treatment group's FA ratio is obviously lower than the ratio of the health control group with P<0.05. There is no difference between the two ratios of the tonifying the kidney group and the health control group with P>0.05. The tonifying the kidney group's ADC ratio is obviously lower than the ratio of the other TCM treatment group. The tonifying the kidney group's FA ratio is obviously higher than the ratio of the other TCM treatment group with P<0.05. The tonifying the kidney group's FA ratio increasing and ADC ratio decreasing margins are obviously wider than the margins of the other TCM treatment group with P<0.05. It shows the tonifying the kidney group's nerve fiber tract repair is obviously better than that of the other TCM treatment group.
Conclusion
1. Compared with the western medicine treatment and other TCM treatment groups, the tonifying the kidney group's TCM clinic and neurologic systematic syndromes decrease obviously after treatment. It shows tonifying the kidney treating MS can effectively improve the clinical syndromes.
2. Compared with the western medicine treatment group, the tonifying the kidney group's EDSS and TCM syndromes scores decrease obviously after treatment. It shows tonifying the kidney treating MS can improve neurologic function remarkably.
3. Compared with the western medicine treatment group, the tonifying the kidney group's NAA/CR ratio increase and CHO/CR ratio decrease obviously after treatment. It shows tonifying the kidney treating MS can effectively promote myelin sheath repair and axon regeneration.
4. Compared with the western medicine treatment and other TCM treatment groups, the tonifying the kidney group's ADC ratio decrease and FA ratio increase obviously after treatment. It shows tonifying the kidney treating MS can effectively promote nerve fiber tract repair.
Above all, tonifying the kidney treating MS can effectively promote the damaged nerve repair and regeneration.
通过检测复发缓解型多发性硬化(Relapsing-Remitting Multiple Sclerosis, RRMS)患者的质子共振波谱分析与弥散张量成像指标,研究并探讨中医补肾法对多发性硬化的髓鞘再生与轴索修复的作用,及其与西药治疗的差异,为中医辨证论治提供临床科学证据。
材料与方法
1.病例来源及分组
入组患者均为2012年9月至2014年1月的就诊于首都医科大学附属北京天坛医院中医科门诊及神经内科门诊病人,并设立健康对照组。临床确诊RRMS患者56例,其中中医科门诊患者40例为中医治疗组,神经内科门诊病例16例为西药治疗组,健康人11例为健康对照组。参照中医辨证分类标准,中医治疗组分为肾虚型和其他证型,其中肾虚型患者29例,为补肾治疗组,其他证型11例,为其他证型治疗组。西药治疗组均为肾虚型。
2.治疗方法与观察指标
(1)治疗方法补肾治疗组肝肾阴虚型予二黄方治疗,脾肾阳虚型与二黄方加附子等治疗；其他证型治疗组主要分为气虚痰瘀型及痰热瘀阻型,依据不同证型给予相应辨证治疗：气虚痰瘀型予黄芪桂枝五物汤,痰热瘀阻型予黄连温胆汤合桃红四物汤治疗；西药治疗组予西医常规治疗。
(2)观察指标及随访周期入组时详细记录各组患者一般资料,包括发病年龄、病程长短、复发次数、中医临床症状分布、神经系统症状分布,进行扩展伤残等级评分(Expended Disability Score Standard, EDSS)及中医症状评分。同时各组患者及健康对照组行头颅核磁检查,记录各组患者及健康对照组核磁质子共振波谱分析(MR Spectroscopy, MRS)及弥散张量成像(Diffusion Tensor Imaging, DTI)。MRS主要检测指标包括：N-乙酰天门冬氨酸(N-acetylaspartate,Naa1、胆碱(Choline,Cho)、总肌酸(Creatine,Cr),藉由病灶侧及正常侧Naa/Cr、Cho/Cr作为评价标准。DTI主要检测指标包括：表观弥散系数(Apparent Diffusion Coefficient, ADC)及各向异性(Fractional Anisotropy, FA)。随访周期为9个月,随访结束时三组RRMS患者再次记录中医及神经症状分布,进行扩展伤残等级评分(Expended Disability Score Standard, EDSS).中医症状评分,及头颅核磁检查,指标同前。
第一部分：观察治疗前补肾治疗组、西药治疗组中医临床症状分布、神经系统症状分布、EDSS评分、中医症状评分的差异,及两组MRS、DTI指标与健康对照组差异,并比较治疗前后补肾治疗组、西药治疗组EDSS评分、中医症状评分、MRS、DTI指标变化。
第二部分：观察治疗前补肾治疗组、其他证型治疗组中医临床症状分布、神经系统症状分布、EDSS评分、中医症状评分的差异,及两组MRS、DTI指标与健康对照组差异,并比较治疗前后补肾治疗组、其他证型治疗组EDSS评分、中医症状评分、MRS、 DTI指标变化。
结果
第一部分FMRI评价补肾为主及西药治疗促进MS神经损伤修复作用的差异
1.中医临床症状分布治疗前：补肾治疗组与西药治疗组患者在中医临床症状分布无显著差异,P>0.05。治疗后：补肾治疗组在身痛、肢体无力、跟跖疼痛、四肢发麻、头晕、头痛、视力模糊、不寐、多梦、小便频急、健忘、急躁易怒及潮热盗汗等例数显著低于西药治疗组,P<0.05,提示补肾治疗组中医临床症状显著缓解。
2.神经系统症状分布治疗前：补肾治疗组与西药治疗组患者在神经系统症状分布无显著差异,P>0.05。治疗后：补肾治疗组在肢体无力、感觉障碍、视力障碍、小便功能障碍、共济失调、大脑皮层功能减退及发作性症状等例数显著低于西药治疗组,P<0.05,提示补肾治疗组神经系统症状显著缓解。
3.EDSS评分及中医症状评分治疗前：补肾治疗组与西药治疗组患者EDSS评分、中医症状评分均无显著差异,P>0.05。治疗后：补肾治疗组EDSS评分、中医症状评分显著低于西药治疗组,P<0.05。两组患者治疗后的EDSS评分及中医症状评分较治疗前均有所下降,而补肾治疗组下降程度更加显著,P<0.05,提示补肾治疗组神经系统功能修复较好。
4.质子共振波谱分析(MRS)治疗前：补肾治疗组及西药治疗组NAA/CR比值均显著低于健康对照组,而CHO/CR比值均显著高于健康对照组,P<0.05,提示两组的髓鞘脱失及轴索损伤显著。两组间无显著差异,P>0.05。治疗后：西药治疗组NAA/CR比值显著低于健康对照组,而CHO/CR比值显著高于健康对照组,P<0.05；补肾治疗组NAA/CR比值及CHO/CR比值均和健康对照组无差异,P>0.05；而其NAA/CR比值显著高于西药治疗组,CHO/CR比值显著低于西药治疗组,P<0.05。补肾治疗组NAA/CR比值上升及CHO/CR比值下降幅度均较西药治疗组显著,P<0.05。上述结果提示补肾治疗组髓鞘修复及轴索再生显著优于西药治疗组。
5.弥散张量成像分析(DTI)治疗前：补肾治疗组及西药治疗组ADC比值均显著高于健康对照组,而FA比值均显著低于健康对照组P<0.05,提示两组神经纤维束损伤显著。两组间无显著差异,P>0.05。治疗后：西药治疗组ADC比值显著高于健康对照组,而FA比值显著低于健康对照组,P<0.05；补肾治疗组ADC比值及FA比值均和健康对照组无差异,P>0.05；而其FA比值显著高于西药治疗组,ADC比值显著低于西药治疗组,P<0.05。补肾治疗组FA比值上升及ADC比值下降幅度均较西药治疗组显著,P<0.05。上述结果提示补肾治疗组神经纤维束修复显著优于西药治疗组。
第二部分FMRI评价中医辨证治疗促进不同证型MS神经损伤修复作用的差异
1.中医临床症状分布治疗前：补肾治疗组与其他证型治疗组患者在中医临床症状分布无显著差异,P>0.05。治疗后：补肾治疗组在筋脉拘挛、头晕、头痛及口干等例数显著低于其他证型治疗组,P<0.05,提示补肾治疗组中医临床症状缓解较佳。
2.神经系统症状分布治疗前：补肾治疗组与其他证型治疗组患者在神经系统症状分布无显著差异,P>0.05。治疗后：补肾治疗组在共济失调例数显著低于其他证型治疗组,P<0.05,提示补肾治疗组神经系统症状缓解较佳。
3EDSS评分及中医症状评分治疗前：补肾治疗组与其他证型治疗组患者EDSS评分、中医症状评分均无显著差异,P>0.05。治疗后：补肾治疗组EDSS及中医症状评分低于其他证型治疗组,但P>0.05,差异无统计学意义,提示补肾治疗组神经系统功能修复趋向较好。
4.质子共振波谱分析(MRS)治疗前：补肾治疗组及其他证型治疗组NAA/CR比值均显著低于健康对照组,而CHO/CR比值均显著高于健康对照组P<0.05,两治疗组间无显著差异,P>0.05。治疗后：其他证型治疗组NAA/CR比值略低于健康对照组,而CHO/CR比值略高于健康对照组,P>0.05；补肾治疗组NAA/CR比值及CHO/CR比值均和健康对照组无差异,P>0.05；而其NAA/CR比值高于其他证型治疗组,CHO/CR比值低于其他证型治疗组,但差异无统计学意义,P>0.05。上述结果提示补肾治疗组髓鞘修复及轴索再生趋向优于其他证型治疗组。
5.弥散张量成像分析(DTI)治疗前：补肾治疗组及其他证型治疗组ADC比值均显著高于健康对照组,而FA比值均显著低于健康对照组,P<0.05,两组间无显著差异,P>0.05。治疗后：其他证型治疗组ADC比值显著高于健康对照组,而FA比值显著低于健康对照组,P<0.05；补肾治疗组ADC比值及FA比值均和健康对照组无差异,P>0.05；而其ADC比值显著低于其他证型治疗组,FA比值显著高于其他证型治疗组,P<0.05。补肾治疗组ADC比值下降及FA比值上升幅度均较其他证型治疗组显著,P<0.05。上述结果提示补肾治疗组神经纤维束修复显著优于其他证型治疗组。
结论
1通过治疗前后比较,补肾治疗组中医临床症状及神经系统症状较西药治疗组及其他证型治疗组显著减少,提示补肾为主治疗MS能有效缓解临床症状。
2通过治疗前后比较,补肾治疗组EDSS及中医症状评分较西药治疗组显著下降,提示补肾为主治疗MS能有效修复神经系统功能。
3通过MRS检测治疗前后数据比较,补肾治疗组Naa/Cr比值较西药治疗组显著上升、Cho/Cr比值较西药治疗组显著下降,提示补肾治疗MS能有效促进髓鞘修复及轴索再生。
4通过DTI检测治疗前后数据比较,补肾治疗组ADC比值均较西药治疗组及其他证型治疗组显著下降、FA比值均较西药治疗组及其他证型治疗组显著上升,提示补肾治疗MS能有效促进神经纤维束修复。
Objective
Compared with the western medicine treatment effects, we research and confer repair and regeneration of myelin sheath, axon and nerve fiber of TCM tonifying the kidney treating the relapsing-remitting multiple sclerosis patients by detecting MR Spectroscopy and Diffusion Tensor Image to provide the TCM diagnosis theory scientific evidence.
Materials and Methods
1. Patient source and division
The experiment patients come from Sep.2012to Jan.2014Beijing Tiantan Hospital TCM and neurology department out-hospital patients. We establish the health control group. There are56diagnosed relapsing remitting multiple sclerosis(RRMS) patients, including40ones from TCM and16ones from the neurology departments. The health control group includes11healthy persons. According to the TCM diagnosis criteria, the TCM patients are divided into the kidney deficiency type and the other TCM types. The tonifying the kidney group includes29kidney deficiency type patients. The other TCM type treatment group includes11the other TCM type patients. The western medicine treatment group includes16kidney deficiency type patients.
2. Treatment and observed indexes
(1) Treatment The tonifying the kidney group patients are given Erhuang formula for Gan Shen yin deficiency ones and Erhuang formula adding Fuzi for Pi Shen yang deficiency ones. The other TCM type treatment group patients are divided into Qi deficiency phlegm stasis type and phlegm heat stasis type. The Qi deficiency phlegm stasis type patients are given Huangqi guizhi wu wu formula and the phlegm heat stasis type ones are given Huanglian wendan formula and Taohong siwu formula. The western medicine treatment patients are given the normal western medicine.
(2) Observed indexes and periods The patients are recorded the general data, including the age of first attack, disease duration, relapsing times, TCM clinic syndromes distribution, neurologic systematic syndromes distribution, Expended Disability Score Standard(EDSS) and TCM syndromes scores. The patients and health control group persons receive MRI detection and are recorded the lesion and normal sides data of MR Spectroscopy(MRS) and Diffusion Tensor Imaging(DTI) data. MRS data include N-acetylaspartate(Naa), Choline(Cho) and Creatine(Cr). The MRS observed indexes include Naa/Cr and Cho/Cr ratios of lesion and normal sides. The DTI observed indexes include Apparent Diffusion Coefficient(ADC) and Fractional Anisotropy(FA) of lesion and normal sides. The observing period is9months. After the continuous9months treatment, the three RRMS patients are recorded TCM and neurologic syndromes distribution. They are evaluated EDSS and TCM syndromes scores. They also receive MRI detection and the observed indexes are mentioned on the above.
Section1:Before treatment, the TCM clinic syndromes distribution, neurologic systematic syndromes distribution, EDSS and TCM syndromes scores difference is observed between the tonifying the kidney and western medicine treatment groups. The MRS and DTI observed indexes difference is compared among the two groups and the health control group. Before and after treatment, the tonifying the kidney and western medicine treatment groups' TCM and neurologic syndromes distribution, EDSS and TCM syndromes scores are compared. Besides, the two groups'MRS and DTI observed indexes changes are compared.
Second2:Before treatment, we observe the TCM clinic syndromes distribution, neurologic systematic syndromes distribution, EDSS and TCM syndromes scores of the tonifying the kidney and other TCM treatment groups. We compare the MRS and DTI indexes difference among the two groups and the health control group. Before and after treatment, we also compare the TCM and neurologic syndromes distribution, EDSS and TCM syndromes scores, MRS and DTI indexes changes between the the tonifying the kidney and other TCM treatment groups.
Results
Section1:FMRI estimate the nerve damage and repair difference between the tonifying the kidngy and western medicine treating MS patients
1. TCM syndromes distribution Before treatment, there is no distribution difference between the tonifying the kidney and western medicine treatment groups with P>0.05. After treatment, the tonifying the kidney group's number of patients complaining bodily pain, impotent limbs, heels irritation, limbs numbness, giddiness, cephalalgia, blurred vision, insomnia, dreamy rest, urgent urination, obliviousness, fidget, hectic fever and night sweat is obviously lowered than the western medicine treatment group's number with P<0.05. It shows the tonifying the kidney group's TCM syndromes get recovery remarkably.
2. Neurologic syndromes distribution Before treatment, there is no distribution difference between the tonifying the kidney and western medicine treatment groups with P>0.05. After treatment, the tonifying the kidney group's number of patients complaining impotent limbs, sensation paralysis, blurred vision, failed urination, ataxia, decreased cerebrum cortex function and relapsing syndromes is obviously lowered than the western medicine treatment group's number with P<0.05. It shows the tonifying the kidney group's neurologic syndromes get recovery remarkably.
3. EDSS and TCM syndromes scores Before treatment, there is no EDSS and TCM syndromes scores difference between the tonifying the kidney and western medicine treatment groups with P>0.05. After treatment, the tonifying the kidney group's EDSS and TCM syndromes scores are obviously lowered than those of the western medicine treatment group with P<0.05. The two groups'EDSS and TCM syndromes scores decrease after treatment. The tonifying the kidney group's EDSS and TCM syndromes scores decrease more obviously with P<0.05. It shows the tonifying the kidney group's neurologic function get recovery remarkably.
4. MR Spectroscopy(MRS) Before treatment, the tonifying the kidney and western medicine treatment groups'NAA/CR ratios are obviously lower and CHO/CR ratios are obviously higher than the ratios of the health control group with P<0.05. It shows the two groups'demyelination and axonal damage is obvious. There is no difference between the ratios of the two groups with P>0.05. After treatment, the western medicine treatment group's NAA/CR ratio is obviously lower than the ratio of the health control group. The western medicine treatment group's CHO/CR ratio is obviously higher than the ratio of the health control group with P<0.05. There is no difference between the two ratios of the tonifying the kidney group and the health control group with P>0.05. The tonifying the kidney group's NAA/CR ratio is obviously higher than the ratio of the western medicine treatment group. The tonifying the kidney group's CHO/CR ratio is obviously lower than the ratio of the western medicine treatment group with P<0.05. The tonifying the kidney group's NAA/CR ratio increasing and CHO/CR ratio decreasing margins are obviously wider than the margins of the western medicine treatment group with P<0.05. It shows the tonifying the kidney group's myelin sheath repair and axon regeneration is obviously better than that of the western medicine treatment group.
5. Diffusion Tensor Imaging(DTI) Before treatment, the tonifying the kidney and western medicine treatment groups'ADC ratios are obviously higher and CHO/CR ratios are obviously lower than the ratios of the health control group with P<0.05. It shows the two groups'nerve fiber damage is obvious. There is no difference between the ratios of the two groups with P>0.05. After treatment, the western medicine treatment group's ADC ratio is obviously higher than the ratio of the health control group. The western medicine treatment group's FA ratio is obviously lower than the ratio of the health control group with P<0.05. There is no difference between the two ratios of the tonifying the kidney group and the health control group with P>0.05. The tonifying the kidney group's FA ratio is obviously higher than the ratio of the western medicine treatment group. The tonifying the kidney group's ADC ratio is obviously lower than the ratio of the western medicine treatment group with P<0.05. The tonifying the kidney group's FA ratio increasing and ADC ratio decreasing margins are obviously wider than the margins of the western medicine treatment group with P<0.05. It shows the tonifying the kidney group's nerve fiber tract repair is obviously better than that of the western medicine treatment group.
Section2:FMRI estimate the nerve damage and repair difference between the different TCM types diagnosing and treating MS patients
1. TCM syndromes distribution Before treatment, there is no distribution difference between the tonifying the kidney and the other TCM treatment groups with P>0.05. After treatment, the tonifying the kidney group's number of patients complaining spasm, giddiness, cephalalgia and thirsty is obviously lowered than the other TCM treatment group's number with P<0.05. It shows the tonifying the kidney group's TCM syndromes get better recovery.
2. Neurologic syndromes distribution Before treatment, there is no distribution difference between the tonifying the kidney and other TCM treatment groups with P>0.05. After treatment, the tonifying the kidney group's number of patients complaining ataxia is obviously lowered than the other TCM treatment group's number with P<0.05. It shows the tonifying the kidney group's neurologic syndromes get better recovery.
3. EDSS and TCM syndromes scores Before treatment, there is no EDSS and TCM syndromes scores difference between the tonifying the kidney and other TCM treatment groups with P>0.05. After treatment, the tonifying the kidney group's EDSS and TCM syndromes scores tend to be lower than those of the other TCM treatment group with P>0.05. The tonifying the kidney group's EDSS and TCM syndromes scores decreasing margins tend to be wider than those of the other TCM treatment group. It shows the tonifying the kidney group's neurologic function tends to get better recovery.
4. MR Spectroscopy(MRS) Before treatment, the tonifying the kidney and other TCM treatment groups'NAA/CR ratios are obviously lower and CHO/CR ratios are obviously higher than the ratios of the health control group with P<0.05. It shows the two groups' demyelination and axonal damage is obvious. There is no difference between the ratios of the two groups with P>0.05. There is no difference among the two ratios of the tonifying the kidney, TCM treatment and the health control groups after treatment with P>0.05. The tonifying the kidney group's NAA/CR ratio tends to be higher than the ratio of the other TCM treatment groups. The tonifying the kidney group's CHO/CR ratio tends to be lower than the ratio of the other TCM treatment group with P<0.05. The tonifying the kidney group's NAA/CR ratio increasing and CHO/CR ratio decreasing margins tend to be wider than the margins of the other TCM treatment group with P>0.05. It shows the tonifying the kidney group's myelin sheath repair and axon regeneration tends to be better than that of the other TCM treatment group.
5. Diffusion Tensor Imaging(DTI) Before treatment, the tonifying the kidney and other TCM treatment groups'ADC ratios are obviously higher and FA ratios are obviously lower than the ratios of the health control group with P<0.05. There is no difference between the ratios of the two groups with P>0.05. After treatment, the other TCM treatment group's ADC ratio is obviously higher than the ratio of the health control group. The other TCM treatment group's FA ratio is obviously lower than the ratio of the health control group with P<0.05. There is no difference between the two ratios of the tonifying the kidney group and the health control group with P>0.05. The tonifying the kidney group's ADC ratio is obviously lower than the ratio of the other TCM treatment group. The tonifying the kidney group's FA ratio is obviously higher than the ratio of the other TCM treatment group with P<0.05. The tonifying the kidney group's FA ratio increasing and ADC ratio decreasing margins are obviously wider than the margins of the other TCM treatment group with P<0.05. It shows the tonifying the kidney group's nerve fiber tract repair is obviously better than that of the other TCM treatment group.
Conclusion
1. Compared with the western medicine treatment and other TCM treatment groups, the tonifying the kidney group's TCM clinic and neurologic systematic syndromes decrease obviously after treatment. It shows tonifying the kidney treating MS can effectively improve the clinical syndromes.
2. Compared with the western medicine treatment group, the tonifying the kidney group's EDSS and TCM syndromes scores decrease obviously after treatment. It shows tonifying the kidney treating MS can improve neurologic function remarkably.
3. Compared with the western medicine treatment group, the tonifying the kidney group's NAA/CR ratio increase and CHO/CR ratio decrease obviously after treatment. It shows tonifying the kidney treating MS can effectively promote myelin sheath repair and axon regeneration.
4. Compared with the western medicine treatment and other TCM treatment groups, the tonifying the kidney group's ADC ratio decrease and FA ratio increase obviously after treatment. It shows tonifying the kidney treating MS can effectively promote nerve fiber tract repair.
Above all, tonifying the kidney treating MS can effectively promote the damaged nerve repair and regeneration.
引文
1赵晖,王蕾,龚慕辛,等.二黄胶囊对实验性自身免疫性脑脊髓炎小鼠细胞免疫的影响[J].首都医科大学学报,2009,30(1)：15-19
2 Yoo DS, Choi WY, Lee SY, et al. Quantitative analysis of white matter on DTI images of patients with tinnitus:Preliminary Report[J]. Medical Bio-Science,2006, 1(10):1870-1872
3殷旭华.MRI在多发性硬化中的应用[J].中华神经免疫学和神经病学杂志,2011,18(3)：217-219
4 Sijens PE, Irwan R, Potze JH, et al. Relationships between brain water content and diffusion tensor imaging parameters (apparent diffusion coefficient and fractional anisotropy) in multiple sclerosis[J]. Radiology,2006,16(4):898-904
5贺丹,杨丽,陈德强,等.多序列磁共振成像在一例多发性硬化诊断中的应用体会[J].脑与神经疾病杂志,2011,19(1)：35-38
6 Sun SW, Liang HF, Schmidt RE, et al. Selective vulnerability of cerebral white matter in a murine model of multiple sclerosis detected using diffusion tensor imaging[J]. Neurobiology,2007,28(1):30-38
7 Mayer D, Zahr NM, Adalsteinsson E, et al. In vivo fiber tracking in the rat brain on a clinical 3T MRI system using a high strength insert gradient coil[J]. Neuroimage,2007, 35(3):1077-1085
8 Yu CS, Lin FC, Liu Y, et al. Histogram analysis of diffusion measures in clinically isolated syndromes and relapsing-remitting multiple sclerosis[J]. Radiology,2007, 10(8):1030-1038
9 Lin F, Yu C, Jiang T, et al. Discriminative analysis of relapsing neuromyelitis optica and relapsing-remitting multiple sclerosis based on two-dimensional histogram from diffusion tensor imaging[J]. AJNR,2006,31(2):543-549
10 Melhem ER, Itoh R, Jones L, et al. Diffusion tensor MR of the brain:effect of diffusion weight on trace and anisotropy measurement[J]. AJNR,2010,21(2):1813-1820
11周福庆,Chi-Shing Zee,龚洪翰,等.多发性硬化早期胼胝体的DTI改变[J].中国临床医学影像杂志,2010,21(4)：233-235
12 Patel S, Hum B, Gonzalez C, et al. Use of a voxel wise approach in the analysis of fractional anisotropy data in multiple sclerosis patients[J]. England Medical Science,2005, 7(7):32-35
13李郁欣,耿道颖,姜兴岳,等.多发性硬化的正常表现脑白质的DTI定量[J].神经影像学杂志,2007,13(3)：148-152
14张雨涵,龚洪翰.多发性硬化基底节功能磁共振成像的研究进展[J].实用放射学杂志,2013,29(12)：2039-2042
15黄薇馨,郑金.多发性硬化患者磁共振弥散张量成像与智能、记忆障碍研究进展[J].内科杂志,2009,4(6)：935-937
16 Dogonowski A M, Siebner H R, S(?)rensen P S, et al. Expanded functional coupling of subcortical nuclei with the motor resting state network in multiple sclerosis[J]. Multiple Sclerosis,2013,19(5):559-566
17黄敏华,郭勇,林伟,等.磁共振弥散加权像在脑脓肿诊断中的临床应用价值[J].海军总医院学报,2007,20(3)：145-148
18张硕,强金伟,张康乐.弥散张量成像对常规性临床应用的初步建立和实现[J].中国生物医学工程学报,2007,26(5)：796-800
19 Zivad inov R, Cox JL. Neuroimaging in multiple sclerosis[J]. Neurobiology,2007, 79(4):449-474
20 Assaf Y, Chapman J, Ben-Bashat D, et al. White matter changes in multiple sclerosis: correlation of q-space diffusion MRI and 1H MRS[J]. Neuroimage,2005,23(6):703-710
21 Zhang D, Snyder A Z, Fox M D, et al. Intrinsic functional relations between human cerebral cortex and thalamus[J]. Neurophysiology,2008,100(4):1740-1748.
22 Silk T J, Vance A, Rinehart N, et al. Structural development of the basal ganglia in attention deficit hyperactivity disorder:a diffusion tensor imaging study[J]. Psychiatry, 2009,172(3):220-225
23 Budde MD, Kim JH, Liang HF, et al. Toward accurate diagnosis of white matter pathology using diffusion tensor imaging[J]. Neuroimage,2007,57(4):688-695
24 Traboulsee A, Dehmeshki J, Peters KR, et al. Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities[J]. Neuroimage,2003, 9(6):566-573
25 Davies GR, Ramio-Torrenta L, Hadjiprocopis A, et al. Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis[J]. Neurosurgery Psychiatry,2004,75(7):998-1002
26 Saindane AM, Law M, Ge Y, et al. Correlation of diffusion tensor and dynamic perfusion MR imaging metrics in normal-appearing corpus callosum:support for primary hypoperfusion in multiple sclerosis[J]. AJNR,2007,28(4):767-772
27 Lin X, Tench CR, Morgan PS, et al. Use of combined conventional and quantitative MRI to quantify pathology related to cognitive impairment in multiple sclerosis[J]. Neurosurg Psychiatry,2008,79(4):437-441
28 Deloire MS, Salort E, Bonnet M, et al. Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis[J]. Neurosurg Psychiatry, 2005,80(4):500-505
29 Zivadinov R, De Masi R, Nasuelli D, et al. MRI techniques and cognitive impairment in the early phase of relapsing-remitting multiple sclerosis[J]. Neuroradiology,2011, 43(4):272-278
30 Reich DS, Zackowski KM, Gordon-Lipkin EM, et al. Corticospinal tract abnormalities are associated with weakness in multiple sclerosis[J]. AJNR,2008,29(2):333-339
31 DeBoy CA, Zhang J, Dike S, et al. High resolution diffusion tensor imaging of axonal damage in focal inflammatory and demyelinating lesions in rat spinal cord[J]. Brain,2007, 13(8):2199-2205
32 Kim JH, Budde MD, Liang HF, et al. Detecting axon damage in spinal cord from a mouse model of multiple sclerosis[J]. Neurobiology,2006,21(3):626-632
33 Reddy H, Narayanan S, Arnoutelis R, et al. Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis [J]. Brain,2004, 12(3):2314-2320
34 Yu CS, Lin FC, Li KC, et al. Diffusion tensor imaging in the assessment of normal-appearing brain tissue damage in relapsing neuromyelitis optica[J]. AJNR,2006, 27(5):1009-1015
35 Song SK, Yoshino J, Le TQ, et al. Demyelination increases radial diffusivity in corpus callosum of mouse brain[J]. Neuroimage,2005,26(1):132-140
36 Hasan KM, Gupta RK, Santos RM, et al. Diffusion tensor fractional anisotropy of the normal-appearing seven segments of the corpus callosum in healthy adults and relapsing-remitting multiple sclerosis patients [J]. Neuroimage,2005,21(6):735-743
37 Ge Y, Law M, Johnson G, et al. Preferential occult injury of corpus callosum in multiple sclerosis measured by diffusion tensor imaging[J]. Neuroimage,2004,20(1):1-7
38 Wilson M, Tench CR, Morgan PS, et al. Pyramidal tract mapping by diffusion tensor magnetic resonance imaging in multiple sclerosis:improving correlations with disability[J]. Neurosurgery Psychiatry,2013,74(2):203-207
39 Ge Y, Law M, Grossman RI. Applications of diffusion tensor MR imaging in multiple sclerosis[J]. Annual New York Academy Science,2005,10(64):202-219
40 Chu SG, Shen TZ, Chen XR. The value of diffusion MR imaging in judging pathological changes of brain multiple sclerosis[J]. Zhonghua Yi Xue Za Zhi,2005,85(35):2513-2517
41陈细香,魏文洲,郑晓华,等.DTI在脊髓型颈椎病中的应用价值[J].中国医学影像技术,2007,23(12)：1860-1862
42 Schmierer K, Wheeler-Kingshott CA, Boulby PA, et al. Diffusion tensor imaging of post mortem multiple sclerosis brain[J]. Neuroimage,2007,35(2):467-477
43 Le Bihan D, Mangin JF, Poupon C, et al. Diffusion tensor imaging:concepts and applications [J]. Neuroimage,2011,13(4):534-546
44 Hesseltine SM, Law M, Babb J, et al. Diffusion tensor imaging in multiple sclerosis: assessment of regional differences in the axial plane within normal-appearing cervical spinal cord[J]. AJNR,2006,27(6):1189-1193
45 Cassol E, Ranjeva JP, Ibarrola D, et al. Diffusion tensor imaging in multiple sclerosis:a tool for monitoring changes in normal-appearing white matter[J]. Multiple Sclerosis,2004, 10(2):188-196
46 Vrenken H, Pouwels PJ, Geurts JJ, et al. Altered diffusion tensor in multiple sclerosis normal-appearing brain tissue:cortical diffusion changes seem related to clinical deterioration[J]. Neuroimage,2006,23(5):628-636
47 Sijens PE, Irwan R, Potze JH, et al. Analysis of the human brain in primary progressive multiple sclerosis with mapping of the spatial distributions using 1H MR spectroscopy and diffusion tensor imaging[J]. Neuroimage,2005,15(8):1686-1693
48 Werring DJ, Clark CA, Barker GJ, et al. Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis[J]. Neuroimage,2009, 52(8):1626-1632
49 Poonawalla AH, Hasan KM, Gupta RK, et al. Diffusion-tensor MR imaging of cortical lesions in multiple sclerosis:initial findings[J]. Neuroimage,2008,246(3):880-886
50 Li BS, Regal J, Soher BJ, et al. Brain metabolite profiles of T1-hypointense lesions in relapsing-remitting multiple sclerosis[J]. AJNR,2013,24(1):68-74
51 Kalkers NF, Vrenken H, Uitdehang BM, et al. Brain atrophy in multiple sclerosis:impact of lesions and of damage of whole brain tissue[J]. Multiple Sclerosis,2012,8(5):410-414
52 Cercignani M, Inglese M, Pagani E, et al. Mean diffusivity and fractional anisotropy histograms in patients with multiple sclerosis[J]. AJNR,2011,22(5):952-958
53 Nusbaum AO, Tang CY, Wei TC, et al. Whole brain diffusion MR histograms differ sbetween MS subtypes[J]. Neurology,2010,54(7):1421-1426
54 Summers P, Staempfli P, Jaermann T, et al. A preliminary study of the effects of trigger timing on diffusion tensor imaging of the human spinal cord[J]. AJNR,2006, 27(9):1952-1961
55 Zhao Xin, Wang Ming Shin, Gao Wei, et al. Visualization of Neuronal Fiber Tracts in White Matter Based on Diffusion Tensor[J]. Biomedical England,2006,23(4):899-902
56 Rashid W, Hadjiprocopis A, Griffin CM, et al. Diffusion tensor imaging of early relapsing-remitting multiple sclerosis with histogram analysis using automated segmentation and brain volume correction[J]. Multiple Sclerosis,2004,10(1):9-15
57 Griffin CM, Chard DT, Ciccarelli O, et al. Diffusion tensor imaging in early relapsing-remitting multiple sclerosis[J]. Multiple Sclerosis,2011,7(5):290-297
58曹伟,谢黎崖,孙洲亮.口服治疗多发性硬化药物-拉喹莫德[J].中国新药与临床杂志,2008,27(11)：853-856
59黄文,焦辉,张微微,等.多发性硬化合并胸腺瘤一例报告[J].中华神经免疫学和神经病学杂志,2002,9(3)：148
60周建,李晋荣.多发性硬化的临床及MRI表现[J].当代医学杂志,2009,15(19)：9-10
61祝骥.小胶质细胞在神经系统疾病中的作用研究进展[J].中国保健营养杂志,2013,4(4)：131
62 Vogt F, Aktas O, Muller-Wielsch K, et al. Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis[J]. Ann. Neurol,2009,66(3):310-322
63 Bartolomei JC, Greer CA. Olfactory ensheathing cells:bridging the gap in spinal cord injury. Neurosurgery[J]. Ann. Neurol,2010,47(5):1057-1069
64 Boyd JG, Skihar V, Kawaja M, et al. Olfactory ensheathing cells:historical perspective and therapeutic potential[J]. Multiple Sclerosis,2013,27(1):49-60
65李康宁,樊永平,陈克龙,等.二黄胶囊对实验性变态反应性脑脊髓炎模型大鼠急性期炎性反应和髓鞘修复的影响[J].首都医科大学学报,2011,32(1)：110-115
66周莉,高颖,邹忆怀,等.详析四诊素材慎思临证技巧—王永炎教授查房实录[J].北京中医药大学学报(中医临床版),2012,19(2)：37-39
67高敏,林木灿,张凯娜,等.地黄合剂(胶囊)治疗急性复发期多发性硬化38例临床观察[J].湖南中医杂志,2008,24(6)：16-17
68朱文浩,高颖.论多发性硬化与肝肾的关系[J].中国中医急症杂志,2012,21(12)：1918-1919
69郑琦,杨涛,徐大鹏,等.补肾方药防治多发性硬化研究述评[J].辽宁中医药大学学报,2011,13(8)：96-98
70李明智,桂绍高,刘大仁,等.多发性硬化的磁共振波谱研究[J].实用临床医学,2008,9(9)：99-101
71陈翠翠,高健生.高健生运用培正固本法治疗多发性硬化临床经验[J].北京中医药杂志,2010,29(1)：25-26
72代建国,张卫华,代敏.痛性周围性神经病变中西医治疗进展[J].中国医药指南,2012,10(8)：372-373
73周星娅.从督脉失约谈针刺治疗多发性硬化[J].吉林中医药杂志,2010,30(3)：236-237
74郭红.脑病证治体会[J].实用中医药杂志,2009,25(1)：58-59
75杨广华,徐红军.郑绍周教授治疗多发性硬化缓解期的经验[J].中国中医药现代远程教育,2010,8(1)：10-11
76王向阳.跟师医案3则[J].中国中医药现代远程教育杂志,2011,9(12)：8-9
77樊永平,吴畏.500例多发性硬化患者中医证候研究[J].北京中医药大学学报,2014,37(1)：68-71
78关东升,李迎霞.中医“治未病”思想在多发性硬化疾病中的应用[J].光明中医杂志,2013,28(7)：1335-1344
79李靖.朱良春医案研读[J].中国实验方剂学杂志,2011,17(3)：238-239
80许军峰,卞金铃.石学敏院士针刺治疗多发性硬化症的经验[J].中华针灸电子杂志,2013,2(2)：8-11
81王立新,陈绍宏.多发性硬化的中医研究进展[J].广西中医学院学报,2011,14(3)：77-78
82牛潘.中医特色治疗多发性硬化症1例[J].临床合理用药杂志,2011,4(6B)：119-120
83车烨炯,裘昌林.裘昌林运用虫类药治疗神经内科疑难杂症经验[J].亚太传统医药杂志,2011,7(12)：47-48
84周佩娟,郑余银.养肝活血法治疗多发性硬化合并周围神经病变的临床研究[J].广 州中医药大学学报,2009,26(6)：529-531
85吴畏,樊永平,胡蕊.多发性硬化及视神经脊髓炎的临床特点和中医证候比较研究[J].北京中医药杂志,2013,32(7)：506-508
86李向辉.健脾补肾通络解毒汤治疗多发性硬化28例[J].光明中医杂志,2012,27(9)：1808-1809
87周德生,马成瑞.223例多发性硬化患者中医辨证分型研究[J].中国中医药信息杂志,2009,16(12)：21-23
88徐秀梅,肖朝阳.中西医结合治疗多发性硬化病38例[J].江西中医药杂志,2011,11(42)：34-36
89乔波,张春红.石学敏院士治疗多发性硬化随诊体会[J].上海针灸杂志,2011,30(7)：449
90蔡浩烨.郑绍周教授治疗多发性硬化的经验[J].中国中医药现代远程教育杂志,2013,11(18)：118-119
91孟闯,付菊花,马云枝.马云枝教授治疗多发性硬化经验[J].中国民间疗法杂志,2010,18(12)：10-11
92陈韫炜.黄芪桂枝五物汤加味治疗多发性硬化30例[J].湖南中医杂志,2006,22(5)：50-5 1
93胡玉英,刘泰,胡跃强,等.中西医结合治疗多发性硬化35例临床研究[J].江苏中医药杂志,2010,42(3)：23-24
94张伟赫,郭改会,焦劲松,等.中西医结合治疗多发性硬化疗效观察[J].2013,48(7)：93-94
95樊永平,尤昱中,陈克龙,等.261例多发性硬化患者临床特点和中医证候分布[J].首都医科大学学报,2012,33(3)：301-306
96刘国华,张振强.补肾通络方治疗多发性硬化30例[J].河南中医杂志,2006,26(11)：41-42
97郑子安,锺相根,贾旭,等.多发性硬化中医辨证与研究思路探讨[J].吉林中医药杂志,2012,32(11)：1092-1094
98况时祥.益肾扶脾法为主治疗多发性硬化18例[J].中国中医药现代远程教育,2007,23(4)：52-53
99马立坚.以痰论治多发性硬化[J].内蒙古中医药杂志,2012,31(8)：122
100杨海峰,吕二保,孙超群.四妙勇安汤合封髓丹治疗多发性硬化[J].中国中医药现代远程教育,2009,7(9)：21-22
101张博,张春红.石学敏院士醒脑开窍针刺法临床实践[J].中华针灸电子杂志,2012,1(2)：1-5
102芦凤琴,阎伟.中西医治疗多发性硬化的研究进展[J].中国乡材医药杂志,2012,19(1)：83-84
103郝小波,中西医结合三步法治疗多发性硬化的体会[J].世界中西医结合杂志,2008,3(12)：186-187
104宁侠,毛丽君.周绍华以益气温阳法治疗神经系统疾病经验[J].北京中医药杂志,2012,31(2)：96-98
1 05张晓雪.补肾益气活血胶囊治疗多发性硬化的实验研究[J].中国中医药科技杂志,2009,16(4)：270-271
106段磊.益气活血化痰汤对多发性硬化临床疗效评价[J].河北医药杂志,2013,35(3)：460-461
107蒋丽霞,高敏,高聪,等.地黄合剂对多发性硬化患者外周血及脑脊液中T淋巴细胞亚群的影响[J].中国中医基础医学杂志,2012,8(6)：449-451
108尚晓琳,高颖,尹岭,等.益肾达络饮对实验性自身免疫性脑脊髓炎MCP-1的影响[J].天津中医药杂志,2006,23(5)：405-407
109吴彦青,高颖.湿热与多发性硬化症候特点的相关性探析[J].中医研杂志,2011,24(1)：7-9
110朱婷,周德生.脊髓型多发性硬化1例[J].疑难病杂志,2009,8(12)：761-762
111宋云良,王美芝.蜂针+刮痧+中药治疗多发性硬化症[J].蜜蜂杂志,2011,28(8)：3
112陈凌,胡万华,支英豪,等.雷公藤多甙治疗多发性硬化病(MS)的临床观察[J].浙江中医药大学学报,2010,34(2)：188-189
113李呈新.针刺背俞穴治疗多发性硬化24例[J].针灸临床杂志,2013,29(4)：42-44
114许军峰,卞金玲,吕建明,等.针刺配合中药治疗外籍多发性硬化症17例[J].河北中医杂志,2013,35(2)：197-198
115蓝海,周莲英.刘友章用中西医结合疗法治疗多发性硬化经验[J].中医杂志,2004,45(7)：497
1常华军,赵薛旭.H磁共振波谱分析、IgG指数对多发性硬化的诊断价值和二者相关性的研究[J].中国现代神经疾病杂志,2012,12(2)：140-142
2赵薛旭,常华军,李作汉,等.’H磁共振波谱分析在评价多发性硬化轴索损害中的临床价值[J].中国神经免疫学和神经病学杂志,2007,14(5)：253-255
3 罗晓,陈少琼,康庄,等.4种罕见脱髓鞘疾病的MRI表现[J].中国医学影像技术,2011,27(2)：281-285
4常华军,赵薛旭,刘文,等.IgG指数在多发性硬化的诊断价值及与’H磁共振波谱分析的代谢产物比率相关性的研究[J].脑与神经病杂志,2008,16(6)：673-675
5殷旭华.MRI在多发性硬化中的应用[J].中国神经免疫学和神经病学杂志,2011,18(3)：217-219
6李郁欣,汤伟军,耿道颖,等.MRS联合DTI技术在多发性硬化中的初步应用[J].临床放射学杂志,2008,27(9)：1145-1149
7周莉,樊永平.二黄方减少多发性硬化轴索损伤和复发的临床研究[J].中国中医药信息杂志,2012,19(8)：14-15
8陈璇,李咏梅,欧阳羽,等.不同回波时间氢质子磁共振波谱多体素技术检出多发性硬化病灶和看似正常脑白质区[J].中国医学影像技术,2011,27(1)：32-36
9贺丹,杨丽,陈德强,等.多序列磁共振成像在一例多发性硬化诊断中的应用体会[J].脑与神经疾病杂志,2011,19(1)：35-38
10初曙光,沈天真.多发性硬化MR研究进展[J].山东医药杂志,2008,48(34)：84-85
11朱新,黄志纯,刘斌,等.听觉皮层网络老化的静息态功能磁共振成像研究[J].东南大学学报(医学版),2012,31(5)：577-581
12孙家瑜,肖家和,周翔平,等.多发性硬化的MRS表现特征评价[J].华西医学杂志,2007,22(1)：51-52
13李明智,桂绍高,刘大仁,等.多发性硬化的磁共振波谱研究[J].实用临床医学杂志,2008,9(9)：99-101
14程晓娟,姜国鑫,程琦.多发性硬化的影像学研究进展[J].内科理论与实践杂志,2008,3(5)：358-360
15杨桂芬,田伟.多发性硬化的组织病理学改变与1H-MRS表现[J].实用放射学杂志,2013,29(12)：2039-2042
16颜立群,侯亚平,耿左军,等.复发缓解型多发性硬化的磁共振波谱表现[J].实用放射学杂志,2011,27(3)：315-318
17于春雨,耿德勤.磁共振波谱成像在神经系统疾病早期诊断中的应用研究进展[J].徐州医学院学报,2010,30(4)：271-274
18孙家栋.磁共振波谱成像技术在中枢神经系统疾病诊断中的临床应用[J].中国医疗设备杂志,2013,28(7)：117-119
19戴西件,龚洪翰,闵友江,等fMRI观察静息态下健康人睡眠剥夺前后脑局部一致性差异[J].中国医学影像技术杂志,2012,28(2)：243-246
20刘虎,范国光,徐克,等.MRI观察精神分裂症静息态下小脑功能连接和解剖连接[J].中国医学影像技术杂志,2011,27(1)：20-26
21吕高攀,赵恒.小波变换在静息态功能数据分析中的应用[J].临床精神医学杂志,2013,23(2)：82-85
22陈井亚,杨明,刘斌孙,等.正常人运动皮质的功能连接网络及其小世界性[J].中国医学影像技术杂志,2013,29(3)：344-348
23桂绍高,龚洪翰,王博,等.多发性硬化(MS)患者静息态视觉网络的脑功能研究[J].江西医药杂志,2013,48(1)：1-4
24乔鹏飞,牛广明,韩晓东.利用低频振幅算法在正常人静息态下的脑性别差异磁共振研究[J].内蒙古医学院学报,2012,34(4)：289-293
25尤昱中,樊永平.多发性硬化肝肾阴虚与脾肾阳虚患者的质子共振波谱分析及弥散张量成像研究[J].北京中医药大学学报,2011,34(4)：277-281
26汤浩,卢青,韩莉,等.抑郁症住院患者静息态的脑磁频谱分析[J].中华精神科杂志,2012,45(6)：345-348
27李伟兰,刘勇,秦文,等.初步观察早期盲人静息状态下的局部脑活动[J].中国医学影像技术杂志,2012,28(9)：1627-1631
28 Zhu Dongjuan, Wang Xunheng, Ruan Zongcai. Numerical study of resting-state fMRI based on kernel ICA[J]. Journal of Southeast University(English Edition),2010,26(1)：78-81
29黄文涛,冯又层.基于静息态fMRI的人脑功能网络的小世界特性[J].华中师范大学 学报(自然科学版),2011,45(4)：565-568
30肖娟,常静玲,高颖.基于静息态网络神经精神类疾病的脑机制研究进展[J].中国康复理论与实践杂志,2013,19(8)：743-747
31庞高峰,王苏弘,任艳玲,等.学龄期儿童认知发展静息态的功能磁共振研究[J].中华医学杂志,2009,89(19)：1313-1317
32杜培锋,杨剑,吕胜富,等.静息态脑区的活动特征研究[J].北京教育学院学报(自然科学版),2011,6(2)：18-23
33孙桂洋,陈井亚,冯源,等.独立成分分析观察不同性别正常人静息态听觉网络差异[J].东南大学学报(医学版),2013,32(3)：279-283
34邵辉丽.静息态默认功能网络磁共振成像研究[J].中国医学影像技术杂志,2009,25(z1)：201-203
35吴亮,王晓东,贾培雷,等.静息态脑功能成像与皮层电刺激定位皮质运动区的对照研究[J].中华神经外科杂志,2012,28(7)：722-725
36武江芬,钱志余,陶玲,等.静息态脑功能网络中核心节点的定位及其方法比较[J].生物医学工程研究杂志,2013,32(3)：145-149
37杨丽琴,林富春,雷皓.静息状态下脑功能连接的磁共振成像研究[J].波谱学杂志,2010,27(3)：326-339
38 Horovitz S G, Fukunaga M, de Zwart J A, et al. Low frequency BOLD fluctuations during resting wake fulness and light sleep:A simultaneous EEG-fMRI study[J]. Human Brain, 2008,29(6):671-682
39 Greicius MD, Kiviniemi V, Tervonen O, et al. Persistent default-mode network connectivity during light sedation[J]. Human Brain,2008,29(9):839-847
40 Boly M, Tshibanda L, Vanhaudenhuyse A, et al. Functional connectivity in the default network during resting state is preserved in a vegetative but not in abrain dead patient[J]. Human Brain,2009,30(2):2393-2400
41 Van den Heuvel MP, Stare CJ, Kahn R S, et al. Efficiency of Functional Brain Networks and Intellectual Per-formance[J]. Neuroscience,2009,29(8):7619-7624.
42 Thomason M E, Chang C E, Glover G H, et al. Default-mode function and task-induced deactivation have over-lapping brain substrates in children[J]. Neuroimage,2008, 41(6):1493-1503
43 Damoiseaux J S, BeckmannC F, Arigita EJ, et al. Reduced resting-state brain activity in the default network in normal aging[J]. Cerebral Cortex,2008,18(11):1856-1864.
44 Van den Heuvel M P, Mand1 R C, Kahn R S, et al. Functionally linked resting-state networks reflect the underlying structural connectivity architecture of the human brain[J]. Human Brain,2009,30(7):312-3141
45黄超,张伟.静息态和活化态星形胶质细胞ASICs亚细胞分布研究[J].南通大学学报(医学版),2013,33(3)：157-161
46石庆丽,燕浩,陈红燕,等.静息态功能磁共振成像及其在认知障碍中的应用[J].中 国康复理论与实践杂志,2013,19(11)：1029-1031
47唐艳,曹芳,王利锋,等.静息态功能性磁共振成像下对精神分裂症的多体素模式分析[J].中南大学学报(医学版),2013,38(1)：26-30
48王丽,姚志剑,卢青,等.静息态下复发抑郁症患者海马的功能连接[J].临床精神医学杂志,2009,19(2)：73-75
49刘敏,张辉.静息态Bold-fMRI在轻度认知障碍和阿尔茨海默病中的应用[J].中国心理卫生杂志,2009,23(9)：680-684
50杨涛,程宇琪,罗春蓉,等.强迫症首次发病未服药患者脑静息态低频振幅研究[J].中华精神科杂志,2011,44(3)：140-144
51王辉,卢洁,李坤成,等.应用静息态功能磁共振成像分数低频振幅技术观察脑梗死患者大脑基线功能的变化[J].中国医学影像技术杂志,2010,26(11)：2041-2044
1曹伟,谢黎崖,孙洲亮.口服治疗多发性硬化药物-拉喹莫德[J].中国新药与临床杂志,2008,27(11)：853-856
2黄文,焦辉,张微微,等.多发性硬化合并胸腺瘤一例报告[J].中华神经免疫学和神经病学杂志,2002,9(3)：148
3迟克强,毛定安,刘利群.儿童多发性硬化10例临床分析[J].中国医师杂志,2010,12(6)：811-812
4任长红,方方.儿童多发性硬化的研究进展[J].中国实用儿科临床杂志,2013,28(12)：942-945
5刘国华,张振强.补肾通络方治疗多发性硬化30例[J].河南中医杂志,2006,26(11)：41-42
6侯玉立,周培斌,刘桂芬.干扰素p治疗复发缓解型多发性硬化疗效分析及安全性评价[J].中国药物与临床杂志,2009,9(1)：21-25
7周建,李晋荣.多发性硬化的临床及MRI表现[J].当代医学杂志,2009,15(19)：9-10
8赵彩蕾,谢晟,肖江喜,等.儿童多发性硬化的临床特点及MRI特征[J].中华放射学杂志,2011,45(10)：942-946
9刘红民,汪桦,吴文娟,等.MRI在脊髓型多发性硬化中的临床价值[J].2011,26(11)：87-89
10祝骥.小胶质细胞在神经系统疾病中的作用研究进展[J].中国保健营养杂志,2013,4(4)：131
11王飞,于春水,李坤成.多发性硬化MRI研究进展[J].中国医学影像技术杂志,2009,25(11)：2132-2134
12翟继良,孙钢.MRI检查在临床诊断多发硬化中的应用[J].医学影像学杂志,2013,23(5)：807-809
13殷旭华.MRI在多发性硬化中的应用[J].中国神经免疫学和神经病学杂志,2011,18(3)：217-219
14张婉莹,陈玲,周颖,等.多发性硬化与妊娠[J].国际妇产科学杂志,2012,39(6)：585-588
15吕回.不同类型多发性硬化患者的神经功能预后分析[J].中国血液流变学杂志,2012,22(1)：52-54
16杨玉红,张志民,何大艳.多发性硬化治疗进展[J].中国基层医药杂志,2011,18(21)：3005-3007
17唐维强,魏世辉.多发性硬化合并眼部运动功能障碍的分析[J].中国中医眼科杂志,2010,20(2)：82-83
18关东升,李迎霞.中医“治未病”思想在多发性硬化疾病中的应用[J].光明中医杂志,2013,28(7)：1335-1344
19牛潘.中医特色治疗多发性硬化症1例[J].临床合理用药杂志,2011,4(6B)：119-120
20李梦秋,胡佳,司洋,等.多发性硬化治疗措施的临床证据评价[J].中国现代神经疾 病杂志,2012,12(2)：152-157
21王家伟,邓娟,戚朝秀,等.多发性硬化与视神经脊髓炎患者的眼部特征及其治疗效果[J].中华眼底病杂志,2010,26(4)：328-330
22董艳玲,李吕力,李瑶宣,等.甲基强的松龙鞘内注射治疗多发性硬化疗效观察[J].山东医药杂志,2010,50(31)：59-60
23万怡,黄燕兴.多发性硬化的中西医诊治[J].中国民族民间医药,2012,21(21)：5-8
24李晨晔,闺晓波.多发性硬化治疗药物新进展[J].国际免疫学杂志,2012,35(2)：163-164
25韩显龙.多发性硬化治疗新进展[J].内蒙古中医药杂志,2013,9(8)：137-138
26赵丽波,张健莉,付宏娟,等.他克莫司对多发性硬化大鼠髓鞘碱性蛋白的动态变化及影响[J].中国医药导报,2012,9(34)：16-17
27杨扬,吴卫平,田书娟,等.降纤药治疗实验性自身免疫性脑脊髓炎小鼠的机制[J].中国免疫学杂志,2011,27(10)：903-909
28赵华,刘智舒,姚长江.多发性硬化与妊娠[J].医学综述杂志,2012,18(10)：1518-1520
29李家伦,毕贵平,戴宇.多发性硬化症药物治疗进展[J].重庆医学杂志,2011,40(4)：388-390
30张晓雪.补肾益气活血胶囊治疗多发性硬化的实验研究[J].中国中医药科技杂志,2009,16(4)：270-271
31刘喷飓,张星虎,周衡,等.干扰素-β-1b治疗多发性硬化的疗效及不良反应观察[J].中国神经免疫学和神经病学杂志,2011,18(1)：37-40
32狄子晖,姚昕璐,付英,等.多发性硬化患者发生骨质疏松的影响因素研究[J].中国全科医学杂志,2013,16(10)：3329-3331
33陈晨,李伟荣,柳青.脑N-乙酰-α-天冬氨酸浓度下降可以预测复发缓解型多发性硬化进展情况[J].中华医学杂志,2012,92(27)：1904
34尤昱中,樊永平.多发性硬化肝肾阴虚与脾肾阳虚患者的质子共振波谱分析及弥散张量成像研究[J].北京中医药大学学报,2011,34(4)：277-281
35张苏明,张励才.N-乙酰天冬氨酸谷氨酸肽酶抑制剂在神经损伤保护中的研究进展[J].中国药理学通报,2013,29(9)：1200-1204
36 Khon O,Filippi M, Freedman MS, et al. Chronic cerebrospinal venous insufficiency and multiple sclerosis[J]. Ann Neurology,2010,67(4):286-290
37段云云,李坤成,刘亚欧,等.应用体素的形态学研究复发缓解型多发性硬化患者的全脑灰质萎缩特[J].中华神经科杂志,2011,44(7)：460-463
38陈少琼,陈世林,胡冰,等.磁共振新技术在多发性硬化的临床应用[J].新医学杂志,2009,40(2)：114-116
39何晓非,周红雨.高级核磁共振成像技术在视神经脊髓炎研究中的应用[J].现代医药卫生杂志,2013,29(16)：2459-2461
40卢彦,于强,王梅,等.多发性硬化患者眼病的临床分析和长期随访[J].中山大学学 报(医学科学版),2009,30(4S)：92-95
41贺丹,杨丽,陈德强,等.多序列磁共振成像在一例多发性硬化诊断中的应用体会[J].脑与神经疾病杂志,2011,19(1)：35-38
42陈璇,李咏梅,欧阳羽,等.不同回波时间氢质子磁共振波谱多体素技术检出多发性硬化病灶和看似正常脑白质区[J].中国医学影像技术,201 1,27(1)：32-36
43李郁欣,初曙光,李振新,等.多发性硬化患者脑灰质损害的MRI表现及扩散张量成像定量研究[J].中华放射学杂志,2008,42(7)：709-713
44周福庆,Chi-Shing Zee,龚洪翰,等.复发一缓解型多发性硬化患者表现正常胼胝体经Hofer's新方案分区的各向异性定量研究[J].实用放射学杂志,2010,26(6)：790-793
45姚青,陈德基,刘克,等.颅脑磁共振弥散张量成像在多发性硬化患者的初步研究[J].广州医学院学报,2011,39(1)：19-23
46周福庆,Chi-Shing Zee,龚洪翰,等.复发-缓解型多发性硬化边缘系统白质纤维束定量DTI改变[J].实用放射学杂志,2010,26(3)：305-308
47樊永平,吴畏.500例多发性硬化患者中医证候研究[J].北京中医药大学学报,2014,37(1)：68-71
48潘玥,李平.李平教授针药并用治疗多发性硬化经验[J].上海针灸杂志,2011,30(12)：859
49赵晖,王蕾,龚慕辛,等.二黄胶囊对实验性自身免疫性脑脊髓炎小鼠细胞免疫的影响[J].首都医科大学学报.2009,30(1)：15-19
50林一聪,董会卿.2010年修订版多发性硬化诊断标准解读[J].中风与神经病杂志,2011,28(8)：764-767
51 Polman CH, Reingold SC, Banwell B, et al. Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria[J]. Ann Neurol,2011,69(2):292-302
52 H. Royden Jones, JR, MD. Netter's Neurology 1st edition[M]. New Jersey:Icon learning systems,2005,29(8):538-557
53 Xiao-Juan Cheng, Li-Zhen Xu. Review of the diagnosis and clinical features of multiple sclerosis in China[J]. Neuroscience,2009,25(1):38-42.
54中华中医药学会.中医内科常见病诊疗指南(西医疾病)[M].中国中医药出版社,2008,249-252
55国家中医药管理局脑病急诊协作组.中风病诊断及疗效评定标准[J].北京：北京中医药大学学报,1996,12(5)：55-57
56李盈,胡学强Th17/Treg失衡在多发性硬化发病和治疗中的意义[J].中国免疫学杂&,2009,6(25):575-576
57 Yulin G, Robert I, Grossman RI. Magnetization-transfer histogram analysis of gray matter in relapsing-remitting multiple sclerosis[J]. AJNR,2011,22(3):470-480
58 Ciccarelli O, Werring DJ, Barker GJ, et al. A study of the mechanisms of normal-appearing white matter damage in multiple sclerosis using diffusion tensor imaging-evidence of Wallerian degeneration[J]. Neurology,2013,250(3):287-292
59汪栋,刘妍,王蕾.髓鞘少突胶质细胞糖蛋白在多发性硬化中的作用[J].医学研究生学报,2010,23(8)：871-875
60黄德晖,吴卫平,蒲传强,等.多发性硬化226例临床分析[J].中国神经免疫学和神经病学杂志,2013,10(3)：152-155
61刘峥,董会卿,贾建平.米托蒽醌在治疗多发性硬化中的应用[J].中华神经科杂志,2012,45(10)：749-751
62 Fanklyn A, Kirstie H, Opstad S.'HMR spectroscopy of brain tumors and masses[J]. NMR Biomedicine,2013,16(9):123-131
63李明智,桂绍高,刘大仁,等.多发性硬化的磁共振波谱研究[J].实用临床医学杂志,2008,9(9)：99-101
64 Michael JF, Fracp AB, Mark JD,et al. Mapping of brain tumor metabolites with proton MR spectroscopic imaging:clinical relevance[J]. Radiology,2012,18(5):675-686
65赵薛旭,常华军,李作汉,等.1H磁共振波谱分析在评价多发性硬化轴索损害中的临床价值[J].中国神经免疫学和神经病学杂志,2007,14(5)：253-255
66杨承志,郑阿娟,徐忠信.磁共振氢波谱分析在多发性硬化研究中应用[J].中国医学影像学杂志,2005,13(1)：50-52
67 Siger-Zajdel M, Selmaj KW. Proton magnetic resonance spectroscopy of norma-lappearing white matter in familial and sporadic multiple sclerosis[J]. Neurology,2005, 252(7):830-832
68 Clarke CE, Lowry M. Systematic review of proton magnetic resonance spectroscopy of the striatum in Parkinsonian syndromes[J]. Neurology,2011,8(6):573-577
69武传华,周建峰,杨涛.1H磁共振波谱在脑多发性硬化诊断中的价值[J].现代诊断与治疗,2005,16(3)：136-139
70周小丰,刘远健.多发性硬化的磁共振扩散张量成像研究[J].医学影像学杂志,2010,20(6)：889-891
71李郁欣,耿道颖.多发性硬化的磁共振弥散张量成像研究[J].医学影像学杂志,2010,20(2)：251-253
72黄薇馨,郑金瓯.多发性硬化患者认知功能损害及核磁共振弥散张量成像研究[J].计算机应用杂志,2013,33(6)：1737-174
73 Kurtzke JF. Rating neurologic impairment in multiple sclerosis:an Expanded Disability Status Scale(EDSS) [M],1983,33:1444-1452
74樊永平,宋丽君,叶明,等.二黄胶囊对实验性自身免疫性脑脊髓炎大鼠中枢神经系统细胞因子和淋巴细胞亚群免疫组化表达的影响[J].中国实验方剂学杂志,2010,16(5)：142-146
75朱文浩,高颖.论多发性硬化与肝肾的关系[J].中国中医急症杂志,2012,21(12)：1918-1919
76郑琦,杨涛,徐大鹏,等.补肾方药防治多发性硬化研究述评[J].辽宁中医药大学学报,2011,13(8)：96-98
77周莉,樊永平,王蕾,等.二黄胶囊对EAE大鼠细胞因子及Th1/Th2平衡的影响.首都医科大学学报,2009,30(1)：20-23
78吴畏,樊永平,胡蕊.多发性硬化及视神经脊髓炎的临床特点和中医证候比较研究[J].北京中医药杂志,2013,32(7)：506-508
79樊永平,周莉,王蕾,等.二黄方对EAE大鼠急性期血浆MCP-1、TNF-α水平的影响[J].北京中医药,2009,28(3)：225-227.
80李康宁,樊永平,陈克龙,等.二黄胶囊对实验性变态反应性脑脊髓炎模型大鼠急性期炎性反应和髓鞘修复的影响[J].首都医科大学学报,2011,32(1)：110-115.
81叶明,樊永平.中药成分与复方防治实验性自身免疫性脑脊髓炎的研究进展[J].北京中医药杂志,2009,28(1)：67-69
82樊永平,宋丽君,叶明,等.左归丸和右归丸对自身免疫性脑脊髓炎大鼠中枢神经系统淋巴细胞亚群免疫组化表达的影响[J].中国中医药信息杂志,2010,17(6)：44-46
83樊永平.寻找中西医脑病之短板,发挥结合医学之优势[J].首都医科大学学报,2009,30(1)：11-14
84郑琦,杨涛,房玲,等.补肾益髓胶囊对实验性自身免疫性脑脊髓炎小鼠大脑内BDNF和NogoA的影响[J].南京中医药大学学报,2013,29(5)：439-444
85周莉,樊永平.二黄方减少多发性硬化轴索损伤和复发的临床研究[J].中国中医药信息杂志,2012,19(8)：14-15
86李菲.中医辨证思维辨证方法与辨证体系[J].辽宁中医杂志,2009,36(2)：213-214
87樊永平,尤昱中,陈克龙,等.261例多发性硬化患者临床特点和中医证候分布[J].首都医科大学学报,2012,33(3)：301-306
88张东友.医学影像学与中医学结合[J].中国中西医结合影像学杂志,2009,7(1)：1-4
89于春水,李坤成.弥散张量成像纤维跟踪技术的研究进展[J].中国医学影像技术,2004,20(3)：477-479
90邝菲,王飞.氢质子磁共振波谱(1H-MRS)技术应用[J].医学影像学杂志,2007,17(8)：871-874
91张海琴,李坤成,于春水,等.磁化传递成像观察多发性硬化大鼠中枢神经系统病灶[J].医学影像学杂志,2011,21(8)：1269-1272
92王德河,李咏梅,吴彤华,等.红细胞生成素水平与多发性硬化合并贫血的相关性[J].中国医学科学院学报,2013,35(1)：84-87
93李勇,管璇,宋兴伟,等.山茱萸总甙对实验性变态性脑脊髓炎大鼠外周一氧化氮的影响[J].浙江中医药大学学报,2012,36(1)：61-63
94王立新,陈绍宏.多发性硬化的中医研究进展[J].广西中医学院学报,2011,14(3)：77-78
95周莉,高颖,邹忆怀,等.详析四诊素材慎思临证技巧—王永炎教授查房实录[J].北京中医药大学学报(中医临床版),2012,19(2)：37-39
96周莉,樊永平.59例多发性硬化患者不同中医证型的免疫学研究[J].中国中西医结合杂志,2007,27(7)：599-601
97郝小波,中西医结合三步法治疗多发性硬化的体会[J].世界中西医结合杂志,2008,3(12)：186-187
98李靖.朱良春医案研读[J].中国实验方剂学杂志,2011,17(3)：238-239
99尚晓琳,高颖,尹岭,等.益肾达络饮对实验性自身免疫性脑脊髓炎MCP-1的影响[J].天津中医药杂志,2006,23(5)：405-407
100陈韫炜.黄芪桂枝五物汤加味治疗多发性硬化30例[J].湖南中医杂志,2006,22(5)：50-51
101王向阳.跟师医案3则[J].中国中医药现代远程教育杂志,2011,9(12)：8-9
102段磊.益气活血化痰汤对多发性硬化临床疗效评价[J].河北医药杂志,2013,35(3)：460-461
103吴彦青,高颖.湿热与多发性硬化症候特点的相关性探析[J].中医研杂志,2011,24(1)：7-9
104吴彦青,高颖,朱陵群,等.实验性自身免疫性脑脊髓炎小鼠中枢神经组织中CD4mRNA对其的影响[J].中国中医急症,2012,21(11)：1760-1762
105孟闯,付菊花,马云枝.马云枝教授治疗多发性硬化经验[J].中国民间疗法杂志,2010,18(12)：10-11
106黄思进.小续命汤临床应用体会[J].中国中医药信息杂志,2012,19(11)：87-88
2 Yoo DS, Choi WY, Lee SY, et al. Quantitative analysis of white matter on DTI images of patients with tinnitus:Preliminary Report[J]. Medical Bio-Science,2006, 1(10):1870-1872
3殷旭华.MRI在多发性硬化中的应用[J].中华神经免疫学和神经病学杂志,2011,18(3)：217-219
4 Sijens PE, Irwan R, Potze JH, et al. Relationships between brain water content and diffusion tensor imaging parameters (apparent diffusion coefficient and fractional anisotropy) in multiple sclerosis[J]. Radiology,2006,16(4):898-904
5贺丹,杨丽,陈德强,等.多序列磁共振成像在一例多发性硬化诊断中的应用体会[J].脑与神经疾病杂志,2011,19(1)：35-38
6 Sun SW, Liang HF, Schmidt RE, et al. Selective vulnerability of cerebral white matter in a murine model of multiple sclerosis detected using diffusion tensor imaging[J]. Neurobiology,2007,28(1):30-38
7 Mayer D, Zahr NM, Adalsteinsson E, et al. In vivo fiber tracking in the rat brain on a clinical 3T MRI system using a high strength insert gradient coil[J]. Neuroimage,2007, 35(3):1077-1085
8 Yu CS, Lin FC, Liu Y, et al. Histogram analysis of diffusion measures in clinically isolated syndromes and relapsing-remitting multiple sclerosis[J]. Radiology,2007, 10(8):1030-1038
9 Lin F, Yu C, Jiang T, et al. Discriminative analysis of relapsing neuromyelitis optica and relapsing-remitting multiple sclerosis based on two-dimensional histogram from diffusion tensor imaging[J]. AJNR,2006,31(2):543-549
10 Melhem ER, Itoh R, Jones L, et al. Diffusion tensor MR of the brain:effect of diffusion weight on trace and anisotropy measurement[J]. AJNR,2010,21(2):1813-1820
11周福庆,Chi-Shing Zee,龚洪翰,等.多发性硬化早期胼胝体的DTI改变[J].中国临床医学影像杂志,2010,21(4)：233-235
12 Patel S, Hum B, Gonzalez C, et al. Use of a voxel wise approach in the analysis of fractional anisotropy data in multiple sclerosis patients[J]. England Medical Science,2005, 7(7):32-35
13李郁欣,耿道颖,姜兴岳,等.多发性硬化的正常表现脑白质的DTI定量[J].神经影像学杂志,2007,13(3)：148-152
14张雨涵,龚洪翰.多发性硬化基底节功能磁共振成像的研究进展[J].实用放射学杂志,2013,29(12)：2039-2042
15黄薇馨,郑金.多发性硬化患者磁共振弥散张量成像与智能、记忆障碍研究进展[J].内科杂志,2009,4(6)：935-937
16 Dogonowski A M, Siebner H R, S(?)rensen P S, et al. Expanded functional coupling of subcortical nuclei with the motor resting state network in multiple sclerosis[J]. Multiple Sclerosis,2013,19(5):559-566
17黄敏华,郭勇,林伟,等.磁共振弥散加权像在脑脓肿诊断中的临床应用价值[J].海军总医院学报,2007,20(3)：145-148
18张硕,强金伟,张康乐.弥散张量成像对常规性临床应用的初步建立和实现[J].中国生物医学工程学报,2007,26(5)：796-800
19 Zivad inov R, Cox JL. Neuroimaging in multiple sclerosis[J]. Neurobiology,2007, 79(4):449-474
20 Assaf Y, Chapman J, Ben-Bashat D, et al. White matter changes in multiple sclerosis: correlation of q-space diffusion MRI and 1H MRS[J]. Neuroimage,2005,23(6):703-710
21 Zhang D, Snyder A Z, Fox M D, et al. Intrinsic functional relations between human cerebral cortex and thalamus[J]. Neurophysiology,2008,100(4):1740-1748.
22 Silk T J, Vance A, Rinehart N, et al. Structural development of the basal ganglia in attention deficit hyperactivity disorder:a diffusion tensor imaging study[J]. Psychiatry, 2009,172(3):220-225
23 Budde MD, Kim JH, Liang HF, et al. Toward accurate diagnosis of white matter pathology using diffusion tensor imaging[J]. Neuroimage,2007,57(4):688-695
24 Traboulsee A, Dehmeshki J, Peters KR, et al. Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities[J]. Neuroimage,2003, 9(6):566-573
25 Davies GR, Ramio-Torrenta L, Hadjiprocopis A, et al. Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis[J]. Neurosurgery Psychiatry,2004,75(7):998-1002
26 Saindane AM, Law M, Ge Y, et al. Correlation of diffusion tensor and dynamic perfusion MR imaging metrics in normal-appearing corpus callosum:support for primary hypoperfusion in multiple sclerosis[J]. AJNR,2007,28(4):767-772
27 Lin X, Tench CR, Morgan PS, et al. Use of combined conventional and quantitative MRI to quantify pathology related to cognitive impairment in multiple sclerosis[J]. Neurosurg Psychiatry,2008,79(4):437-441
28 Deloire MS, Salort E, Bonnet M, et al. Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis[J]. Neurosurg Psychiatry, 2005,80(4):500-505
29 Zivadinov R, De Masi R, Nasuelli D, et al. MRI techniques and cognitive impairment in the early phase of relapsing-remitting multiple sclerosis[J]. Neuroradiology,2011, 43(4):272-278
30 Reich DS, Zackowski KM, Gordon-Lipkin EM, et al. Corticospinal tract abnormalities are associated with weakness in multiple sclerosis[J]. AJNR,2008,29(2):333-339
31 DeBoy CA, Zhang J, Dike S, et al. High resolution diffusion tensor imaging of axonal damage in focal inflammatory and demyelinating lesions in rat spinal cord[J]. Brain,2007, 13(8):2199-2205
32 Kim JH, Budde MD, Liang HF, et al. Detecting axon damage in spinal cord from a mouse model of multiple sclerosis[J]. Neurobiology,2006,21(3):626-632
33 Reddy H, Narayanan S, Arnoutelis R, et al. Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis [J]. Brain,2004, 12(3):2314-2320
34 Yu CS, Lin FC, Li KC, et al. Diffusion tensor imaging in the assessment of normal-appearing brain tissue damage in relapsing neuromyelitis optica[J]. AJNR,2006, 27(5):1009-1015
35 Song SK, Yoshino J, Le TQ, et al. Demyelination increases radial diffusivity in corpus callosum of mouse brain[J]. Neuroimage,2005,26(1):132-140
36 Hasan KM, Gupta RK, Santos RM, et al. Diffusion tensor fractional anisotropy of the normal-appearing seven segments of the corpus callosum in healthy adults and relapsing-remitting multiple sclerosis patients [J]. Neuroimage,2005,21(6):735-743
37 Ge Y, Law M, Johnson G, et al. Preferential occult injury of corpus callosum in multiple sclerosis measured by diffusion tensor imaging[J]. Neuroimage,2004,20(1):1-7
38 Wilson M, Tench CR, Morgan PS, et al. Pyramidal tract mapping by diffusion tensor magnetic resonance imaging in multiple sclerosis:improving correlations with disability[J]. Neurosurgery Psychiatry,2013,74(2):203-207
39 Ge Y, Law M, Grossman RI. Applications of diffusion tensor MR imaging in multiple sclerosis[J]. Annual New York Academy Science,2005,10(64):202-219
40 Chu SG, Shen TZ, Chen XR. The value of diffusion MR imaging in judging pathological changes of brain multiple sclerosis[J]. Zhonghua Yi Xue Za Zhi,2005,85(35):2513-2517
41陈细香,魏文洲,郑晓华,等.DTI在脊髓型颈椎病中的应用价值[J].中国医学影像技术,2007,23(12)：1860-1862
42 Schmierer K, Wheeler-Kingshott CA, Boulby PA, et al. Diffusion tensor imaging of post mortem multiple sclerosis brain[J]. Neuroimage,2007,35(2):467-477
43 Le Bihan D, Mangin JF, Poupon C, et al. Diffusion tensor imaging:concepts and applications [J]. Neuroimage,2011,13(4):534-546
44 Hesseltine SM, Law M, Babb J, et al. Diffusion tensor imaging in multiple sclerosis: assessment of regional differences in the axial plane within normal-appearing cervical spinal cord[J]. AJNR,2006,27(6):1189-1193
45 Cassol E, Ranjeva JP, Ibarrola D, et al. Diffusion tensor imaging in multiple sclerosis:a tool for monitoring changes in normal-appearing white matter[J]. Multiple Sclerosis,2004, 10(2):188-196
46 Vrenken H, Pouwels PJ, Geurts JJ, et al. Altered diffusion tensor in multiple sclerosis normal-appearing brain tissue:cortical diffusion changes seem related to clinical deterioration[J]. Neuroimage,2006,23(5):628-636
47 Sijens PE, Irwan R, Potze JH, et al. Analysis of the human brain in primary progressive multiple sclerosis with mapping of the spatial distributions using 1H MR spectroscopy and diffusion tensor imaging[J]. Neuroimage,2005,15(8):1686-1693
48 Werring DJ, Clark CA, Barker GJ, et al. Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis[J]. Neuroimage,2009, 52(8):1626-1632
49 Poonawalla AH, Hasan KM, Gupta RK, et al. Diffusion-tensor MR imaging of cortical lesions in multiple sclerosis:initial findings[J]. Neuroimage,2008,246(3):880-886
50 Li BS, Regal J, Soher BJ, et al. Brain metabolite profiles of T1-hypointense lesions in relapsing-remitting multiple sclerosis[J]. AJNR,2013,24(1):68-74
51 Kalkers NF, Vrenken H, Uitdehang BM, et al. Brain atrophy in multiple sclerosis:impact of lesions and of damage of whole brain tissue[J]. Multiple Sclerosis,2012,8(5):410-414
52 Cercignani M, Inglese M, Pagani E, et al. Mean diffusivity and fractional anisotropy histograms in patients with multiple sclerosis[J]. AJNR,2011,22(5):952-958
53 Nusbaum AO, Tang CY, Wei TC, et al. Whole brain diffusion MR histograms differ sbetween MS subtypes[J]. Neurology,2010,54(7):1421-1426
54 Summers P, Staempfli P, Jaermann T, et al. A preliminary study of the effects of trigger timing on diffusion tensor imaging of the human spinal cord[J]. AJNR,2006, 27(9):1952-1961
55 Zhao Xin, Wang Ming Shin, Gao Wei, et al. Visualization of Neuronal Fiber Tracts in White Matter Based on Diffusion Tensor[J]. Biomedical England,2006,23(4):899-902
56 Rashid W, Hadjiprocopis A, Griffin CM, et al. Diffusion tensor imaging of early relapsing-remitting multiple sclerosis with histogram analysis using automated segmentation and brain volume correction[J]. Multiple Sclerosis,2004,10(1):9-15
57 Griffin CM, Chard DT, Ciccarelli O, et al. Diffusion tensor imaging in early relapsing-remitting multiple sclerosis[J]. Multiple Sclerosis,2011,7(5):290-297
58曹伟,谢黎崖,孙洲亮.口服治疗多发性硬化药物-拉喹莫德[J].中国新药与临床杂志,2008,27(11)：853-856
59黄文,焦辉,张微微,等.多发性硬化合并胸腺瘤一例报告[J].中华神经免疫学和神经病学杂志,2002,9(3)：148
60周建,李晋荣.多发性硬化的临床及MRI表现[J].当代医学杂志,2009,15(19)：9-10
61祝骥.小胶质细胞在神经系统疾病中的作用研究进展[J].中国保健营养杂志,2013,4(4)：131
62 Vogt F, Aktas O, Muller-Wielsch K, et al. Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis[J]. Ann. Neurol,2009,66(3):310-322
63 Bartolomei JC, Greer CA. Olfactory ensheathing cells:bridging the gap in spinal cord injury. Neurosurgery[J]. Ann. Neurol,2010,47(5):1057-1069
64 Boyd JG, Skihar V, Kawaja M, et al. Olfactory ensheathing cells:historical perspective and therapeutic potential[J]. Multiple Sclerosis,2013,27(1):49-60
65李康宁,樊永平,陈克龙,等.二黄胶囊对实验性变态反应性脑脊髓炎模型大鼠急性期炎性反应和髓鞘修复的影响[J].首都医科大学学报,2011,32(1)：110-115
66周莉,高颖,邹忆怀,等.详析四诊素材慎思临证技巧—王永炎教授查房实录[J].北京中医药大学学报(中医临床版),2012,19(2)：37-39
67高敏,林木灿,张凯娜,等.地黄合剂(胶囊)治疗急性复发期多发性硬化38例临床观察[J].湖南中医杂志,2008,24(6)：16-17
68朱文浩,高颖.论多发性硬化与肝肾的关系[J].中国中医急症杂志,2012,21(12)：1918-1919
69郑琦,杨涛,徐大鹏,等.补肾方药防治多发性硬化研究述评[J].辽宁中医药大学学报,2011,13(8)：96-98
70李明智,桂绍高,刘大仁,等.多发性硬化的磁共振波谱研究[J].实用临床医学,2008,9(9)：99-101
71陈翠翠,高健生.高健生运用培正固本法治疗多发性硬化临床经验[J].北京中医药杂志,2010,29(1)：25-26
72代建国,张卫华,代敏.痛性周围性神经病变中西医治疗进展[J].中国医药指南,2012,10(8)：372-373
73周星娅.从督脉失约谈针刺治疗多发性硬化[J].吉林中医药杂志,2010,30(3)：236-237
74郭红.脑病证治体会[J].实用中医药杂志,2009,25(1)：58-59
75杨广华,徐红军.郑绍周教授治疗多发性硬化缓解期的经验[J].中国中医药现代远程教育,2010,8(1)：10-11
76王向阳.跟师医案3则[J].中国中医药现代远程教育杂志,2011,9(12)：8-9
77樊永平,吴畏.500例多发性硬化患者中医证候研究[J].北京中医药大学学报,2014,37(1)：68-71
78关东升,李迎霞.中医“治未病”思想在多发性硬化疾病中的应用[J].光明中医杂志,2013,28(7)：1335-1344
79李靖.朱良春医案研读[J].中国实验方剂学杂志,2011,17(3)：238-239
80许军峰,卞金铃.石学敏院士针刺治疗多发性硬化症的经验[J].中华针灸电子杂志,2013,2(2)：8-11
81王立新,陈绍宏.多发性硬化的中医研究进展[J].广西中医学院学报,2011,14(3)：77-78
82牛潘.中医特色治疗多发性硬化症1例[J].临床合理用药杂志,2011,4(6B)：119-120
83车烨炯,裘昌林.裘昌林运用虫类药治疗神经内科疑难杂症经验[J].亚太传统医药杂志,2011,7(12)：47-48
84周佩娟,郑余银.养肝活血法治疗多发性硬化合并周围神经病变的临床研究[J].广 州中医药大学学报,2009,26(6)：529-531
85吴畏,樊永平,胡蕊.多发性硬化及视神经脊髓炎的临床特点和中医证候比较研究[J].北京中医药杂志,2013,32(7)：506-508
86李向辉.健脾补肾通络解毒汤治疗多发性硬化28例[J].光明中医杂志,2012,27(9)：1808-1809
87周德生,马成瑞.223例多发性硬化患者中医辨证分型研究[J].中国中医药信息杂志,2009,16(12)：21-23
88徐秀梅,肖朝阳.中西医结合治疗多发性硬化病38例[J].江西中医药杂志,2011,11(42)：34-36
89乔波,张春红.石学敏院士治疗多发性硬化随诊体会[J].上海针灸杂志,2011,30(7)：449
90蔡浩烨.郑绍周教授治疗多发性硬化的经验[J].中国中医药现代远程教育杂志,2013,11(18)：118-119
91孟闯,付菊花,马云枝.马云枝教授治疗多发性硬化经验[J].中国民间疗法杂志,2010,18(12)：10-11
92陈韫炜.黄芪桂枝五物汤加味治疗多发性硬化30例[J].湖南中医杂志,2006,22(5)：50-5 1
93胡玉英,刘泰,胡跃强,等.中西医结合治疗多发性硬化35例临床研究[J].江苏中医药杂志,2010,42(3)：23-24
94张伟赫,郭改会,焦劲松,等.中西医结合治疗多发性硬化疗效观察[J].2013,48(7)：93-94
95樊永平,尤昱中,陈克龙,等.261例多发性硬化患者临床特点和中医证候分布[J].首都医科大学学报,2012,33(3)：301-306
96刘国华,张振强.补肾通络方治疗多发性硬化30例[J].河南中医杂志,2006,26(11)：41-42
97郑子安,锺相根,贾旭,等.多发性硬化中医辨证与研究思路探讨[J].吉林中医药杂志,2012,32(11)：1092-1094
98况时祥.益肾扶脾法为主治疗多发性硬化18例[J].中国中医药现代远程教育,2007,23(4)：52-53
99马立坚.以痰论治多发性硬化[J].内蒙古中医药杂志,2012,31(8)：122
100杨海峰,吕二保,孙超群.四妙勇安汤合封髓丹治疗多发性硬化[J].中国中医药现代远程教育,2009,7(9)：21-22
101张博,张春红.石学敏院士醒脑开窍针刺法临床实践[J].中华针灸电子杂志,2012,1(2)：1-5
102芦凤琴,阎伟.中西医治疗多发性硬化的研究进展[J].中国乡材医药杂志,2012,19(1)：83-84
103郝小波,中西医结合三步法治疗多发性硬化的体会[J].世界中西医结合杂志,2008,3(12)：186-187
104宁侠,毛丽君.周绍华以益气温阳法治疗神经系统疾病经验[J].北京中医药杂志,2012,31(2)：96-98
1 05张晓雪.补肾益气活血胶囊治疗多发性硬化的实验研究[J].中国中医药科技杂志,2009,16(4)：270-271
106段磊.益气活血化痰汤对多发性硬化临床疗效评价[J].河北医药杂志,2013,35(3)：460-461
107蒋丽霞,高敏,高聪,等.地黄合剂对多发性硬化患者外周血及脑脊液中T淋巴细胞亚群的影响[J].中国中医基础医学杂志,2012,8(6)：449-451
108尚晓琳,高颖,尹岭,等.益肾达络饮对实验性自身免疫性脑脊髓炎MCP-1的影响[J].天津中医药杂志,2006,23(5)：405-407
109吴彦青,高颖.湿热与多发性硬化症候特点的相关性探析[J].中医研杂志,2011,24(1)：7-9
110朱婷,周德生.脊髓型多发性硬化1例[J].疑难病杂志,2009,8(12)：761-762
111宋云良,王美芝.蜂针+刮痧+中药治疗多发性硬化症[J].蜜蜂杂志,2011,28(8)：3
112陈凌,胡万华,支英豪,等.雷公藤多甙治疗多发性硬化病(MS)的临床观察[J].浙江中医药大学学报,2010,34(2)：188-189
113李呈新.针刺背俞穴治疗多发性硬化24例[J].针灸临床杂志,2013,29(4)：42-44
114许军峰,卞金玲,吕建明,等.针刺配合中药治疗外籍多发性硬化症17例[J].河北中医杂志,2013,35(2)：197-198
115蓝海,周莲英.刘友章用中西医结合疗法治疗多发性硬化经验[J].中医杂志,2004,45(7)：497
1常华军,赵薛旭.H磁共振波谱分析、IgG指数对多发性硬化的诊断价值和二者相关性的研究[J].中国现代神经疾病杂志,2012,12(2)：140-142
2赵薛旭,常华军,李作汉,等.’H磁共振波谱分析在评价多发性硬化轴索损害中的临床价值[J].中国神经免疫学和神经病学杂志,2007,14(5)：253-255
3 罗晓,陈少琼,康庄,等.4种罕见脱髓鞘疾病的MRI表现[J].中国医学影像技术,2011,27(2)：281-285
4常华军,赵薛旭,刘文,等.IgG指数在多发性硬化的诊断价值及与’H磁共振波谱分析的代谢产物比率相关性的研究[J].脑与神经病杂志,2008,16(6)：673-675
5殷旭华.MRI在多发性硬化中的应用[J].中国神经免疫学和神经病学杂志,2011,18(3)：217-219
6李郁欣,汤伟军,耿道颖,等.MRS联合DTI技术在多发性硬化中的初步应用[J].临床放射学杂志,2008,27(9)：1145-1149
7周莉,樊永平.二黄方减少多发性硬化轴索损伤和复发的临床研究[J].中国中医药信息杂志,2012,19(8)：14-15
8陈璇,李咏梅,欧阳羽,等.不同回波时间氢质子磁共振波谱多体素技术检出多发性硬化病灶和看似正常脑白质区[J].中国医学影像技术,2011,27(1)：32-36
9贺丹,杨丽,陈德强,等.多序列磁共振成像在一例多发性硬化诊断中的应用体会[J].脑与神经疾病杂志,2011,19(1)：35-38
10初曙光,沈天真.多发性硬化MR研究进展[J].山东医药杂志,2008,48(34)：84-85
11朱新,黄志纯,刘斌,等.听觉皮层网络老化的静息态功能磁共振成像研究[J].东南大学学报(医学版),2012,31(5)：577-581
12孙家瑜,肖家和,周翔平,等.多发性硬化的MRS表现特征评价[J].华西医学杂志,2007,22(1)：51-52
13李明智,桂绍高,刘大仁,等.多发性硬化的磁共振波谱研究[J].实用临床医学杂志,2008,9(9)：99-101
14程晓娟,姜国鑫,程琦.多发性硬化的影像学研究进展[J].内科理论与实践杂志,2008,3(5)：358-360
15杨桂芬,田伟.多发性硬化的组织病理学改变与1H-MRS表现[J].实用放射学杂志,2013,29(12)：2039-2042
16颜立群,侯亚平,耿左军,等.复发缓解型多发性硬化的磁共振波谱表现[J].实用放射学杂志,2011,27(3)：315-318
17于春雨,耿德勤.磁共振波谱成像在神经系统疾病早期诊断中的应用研究进展[J].徐州医学院学报,2010,30(4)：271-274
18孙家栋.磁共振波谱成像技术在中枢神经系统疾病诊断中的临床应用[J].中国医疗设备杂志,2013,28(7)：117-119
19戴西件,龚洪翰,闵友江,等fMRI观察静息态下健康人睡眠剥夺前后脑局部一致性差异[J].中国医学影像技术杂志,2012,28(2)：243-246
20刘虎,范国光,徐克,等.MRI观察精神分裂症静息态下小脑功能连接和解剖连接[J].中国医学影像技术杂志,2011,27(1)：20-26
21吕高攀,赵恒.小波变换在静息态功能数据分析中的应用[J].临床精神医学杂志,2013,23(2)：82-85
22陈井亚,杨明,刘斌孙,等.正常人运动皮质的功能连接网络及其小世界性[J].中国医学影像技术杂志,2013,29(3)：344-348
23桂绍高,龚洪翰,王博,等.多发性硬化(MS)患者静息态视觉网络的脑功能研究[J].江西医药杂志,2013,48(1)：1-4
24乔鹏飞,牛广明,韩晓东.利用低频振幅算法在正常人静息态下的脑性别差异磁共振研究[J].内蒙古医学院学报,2012,34(4)：289-293
25尤昱中,樊永平.多发性硬化肝肾阴虚与脾肾阳虚患者的质子共振波谱分析及弥散张量成像研究[J].北京中医药大学学报,2011,34(4)：277-281
26汤浩,卢青,韩莉,等.抑郁症住院患者静息态的脑磁频谱分析[J].中华精神科杂志,2012,45(6)：345-348
27李伟兰,刘勇,秦文,等.初步观察早期盲人静息状态下的局部脑活动[J].中国医学影像技术杂志,2012,28(9)：1627-1631
28 Zhu Dongjuan, Wang Xunheng, Ruan Zongcai. Numerical study of resting-state fMRI based on kernel ICA[J]. Journal of Southeast University(English Edition),2010,26(1)：78-81
29黄文涛,冯又层.基于静息态fMRI的人脑功能网络的小世界特性[J].华中师范大学 学报(自然科学版),2011,45(4)：565-568
30肖娟,常静玲,高颖.基于静息态网络神经精神类疾病的脑机制研究进展[J].中国康复理论与实践杂志,2013,19(8)：743-747
31庞高峰,王苏弘,任艳玲,等.学龄期儿童认知发展静息态的功能磁共振研究[J].中华医学杂志,2009,89(19)：1313-1317
32杜培锋,杨剑,吕胜富,等.静息态脑区的活动特征研究[J].北京教育学院学报(自然科学版),2011,6(2)：18-23
33孙桂洋,陈井亚,冯源,等.独立成分分析观察不同性别正常人静息态听觉网络差异[J].东南大学学报(医学版),2013,32(3)：279-283
34邵辉丽.静息态默认功能网络磁共振成像研究[J].中国医学影像技术杂志,2009,25(z1)：201-203
35吴亮,王晓东,贾培雷,等.静息态脑功能成像与皮层电刺激定位皮质运动区的对照研究[J].中华神经外科杂志,2012,28(7)：722-725
36武江芬,钱志余,陶玲,等.静息态脑功能网络中核心节点的定位及其方法比较[J].生物医学工程研究杂志,2013,32(3)：145-149
37杨丽琴,林富春,雷皓.静息状态下脑功能连接的磁共振成像研究[J].波谱学杂志,2010,27(3)：326-339
38 Horovitz S G, Fukunaga M, de Zwart J A, et al. Low frequency BOLD fluctuations during resting wake fulness and light sleep:A simultaneous EEG-fMRI study[J]. Human Brain, 2008,29(6):671-682
39 Greicius MD, Kiviniemi V, Tervonen O, et al. Persistent default-mode network connectivity during light sedation[J]. Human Brain,2008,29(9):839-847
40 Boly M, Tshibanda L, Vanhaudenhuyse A, et al. Functional connectivity in the default network during resting state is preserved in a vegetative but not in abrain dead patient[J]. Human Brain,2009,30(2):2393-2400
41 Van den Heuvel MP, Stare CJ, Kahn R S, et al. Efficiency of Functional Brain Networks and Intellectual Per-formance[J]. Neuroscience,2009,29(8):7619-7624.
42 Thomason M E, Chang C E, Glover G H, et al. Default-mode function and task-induced deactivation have over-lapping brain substrates in children[J]. Neuroimage,2008, 41(6):1493-1503
43 Damoiseaux J S, BeckmannC F, Arigita EJ, et al. Reduced resting-state brain activity in the default network in normal aging[J]. Cerebral Cortex,2008,18(11):1856-1864.
44 Van den Heuvel M P, Mand1 R C, Kahn R S, et al. Functionally linked resting-state networks reflect the underlying structural connectivity architecture of the human brain[J]. Human Brain,2009,30(7):312-3141
45黄超,张伟.静息态和活化态星形胶质细胞ASICs亚细胞分布研究[J].南通大学学报(医学版),2013,33(3)：157-161
46石庆丽,燕浩,陈红燕,等.静息态功能磁共振成像及其在认知障碍中的应用[J].中 国康复理论与实践杂志,2013,19(11)：1029-1031
47唐艳,曹芳,王利锋,等.静息态功能性磁共振成像下对精神分裂症的多体素模式分析[J].中南大学学报(医学版),2013,38(1)：26-30
48王丽,姚志剑,卢青,等.静息态下复发抑郁症患者海马的功能连接[J].临床精神医学杂志,2009,19(2)：73-75
49刘敏,张辉.静息态Bold-fMRI在轻度认知障碍和阿尔茨海默病中的应用[J].中国心理卫生杂志,2009,23(9)：680-684
50杨涛,程宇琪,罗春蓉,等.强迫症首次发病未服药患者脑静息态低频振幅研究[J].中华精神科杂志,2011,44(3)：140-144
51王辉,卢洁,李坤成,等.应用静息态功能磁共振成像分数低频振幅技术观察脑梗死患者大脑基线功能的变化[J].中国医学影像技术杂志,2010,26(11)：2041-2044
1曹伟,谢黎崖,孙洲亮.口服治疗多发性硬化药物-拉喹莫德[J].中国新药与临床杂志,2008,27(11)：853-856
2黄文,焦辉,张微微,等.多发性硬化合并胸腺瘤一例报告[J].中华神经免疫学和神经病学杂志,2002,9(3)：148
3迟克强,毛定安,刘利群.儿童多发性硬化10例临床分析[J].中国医师杂志,2010,12(6)：811-812
4任长红,方方.儿童多发性硬化的研究进展[J].中国实用儿科临床杂志,2013,28(12)：942-945
5刘国华,张振强.补肾通络方治疗多发性硬化30例[J].河南中医杂志,2006,26(11)：41-42
6侯玉立,周培斌,刘桂芬.干扰素p治疗复发缓解型多发性硬化疗效分析及安全性评价[J].中国药物与临床杂志,2009,9(1)：21-25
7周建,李晋荣.多发性硬化的临床及MRI表现[J].当代医学杂志,2009,15(19)：9-10
8赵彩蕾,谢晟,肖江喜,等.儿童多发性硬化的临床特点及MRI特征[J].中华放射学杂志,2011,45(10)：942-946
9刘红民,汪桦,吴文娟,等.MRI在脊髓型多发性硬化中的临床价值[J].2011,26(11)：87-89
10祝骥.小胶质细胞在神经系统疾病中的作用研究进展[J].中国保健营养杂志,2013,4(4)：131
11王飞,于春水,李坤成.多发性硬化MRI研究进展[J].中国医学影像技术杂志,2009,25(11)：2132-2134
12翟继良,孙钢.MRI检查在临床诊断多发硬化中的应用[J].医学影像学杂志,2013,23(5)：807-809
13殷旭华.MRI在多发性硬化中的应用[J].中国神经免疫学和神经病学杂志,2011,18(3)：217-219
14张婉莹,陈玲,周颖,等.多发性硬化与妊娠[J].国际妇产科学杂志,2012,39(6)：585-588
15吕回.不同类型多发性硬化患者的神经功能预后分析[J].中国血液流变学杂志,2012,22(1)：52-54
16杨玉红,张志民,何大艳.多发性硬化治疗进展[J].中国基层医药杂志,2011,18(21)：3005-3007
17唐维强,魏世辉.多发性硬化合并眼部运动功能障碍的分析[J].中国中医眼科杂志,2010,20(2)：82-83
18关东升,李迎霞.中医“治未病”思想在多发性硬化疾病中的应用[J].光明中医杂志,2013,28(7)：1335-1344
19牛潘.中医特色治疗多发性硬化症1例[J].临床合理用药杂志,2011,4(6B)：119-120
20李梦秋,胡佳,司洋,等.多发性硬化治疗措施的临床证据评价[J].中国现代神经疾 病杂志,2012,12(2)：152-157
21王家伟,邓娟,戚朝秀,等.多发性硬化与视神经脊髓炎患者的眼部特征及其治疗效果[J].中华眼底病杂志,2010,26(4)：328-330
22董艳玲,李吕力,李瑶宣,等.甲基强的松龙鞘内注射治疗多发性硬化疗效观察[J].山东医药杂志,2010,50(31)：59-60
23万怡,黄燕兴.多发性硬化的中西医诊治[J].中国民族民间医药,2012,21(21)：5-8
24李晨晔,闺晓波.多发性硬化治疗药物新进展[J].国际免疫学杂志,2012,35(2)：163-164
25韩显龙.多发性硬化治疗新进展[J].内蒙古中医药杂志,2013,9(8)：137-138
26赵丽波,张健莉,付宏娟,等.他克莫司对多发性硬化大鼠髓鞘碱性蛋白的动态变化及影响[J].中国医药导报,2012,9(34)：16-17
27杨扬,吴卫平,田书娟,等.降纤药治疗实验性自身免疫性脑脊髓炎小鼠的机制[J].中国免疫学杂志,2011,27(10)：903-909
28赵华,刘智舒,姚长江.多发性硬化与妊娠[J].医学综述杂志,2012,18(10)：1518-1520
29李家伦,毕贵平,戴宇.多发性硬化症药物治疗进展[J].重庆医学杂志,2011,40(4)：388-390
30张晓雪.补肾益气活血胶囊治疗多发性硬化的实验研究[J].中国中医药科技杂志,2009,16(4)：270-271
31刘喷飓,张星虎,周衡,等.干扰素-β-1b治疗多发性硬化的疗效及不良反应观察[J].中国神经免疫学和神经病学杂志,2011,18(1)：37-40
32狄子晖,姚昕璐,付英,等.多发性硬化患者发生骨质疏松的影响因素研究[J].中国全科医学杂志,2013,16(10)：3329-3331
33陈晨,李伟荣,柳青.脑N-乙酰-α-天冬氨酸浓度下降可以预测复发缓解型多发性硬化进展情况[J].中华医学杂志,2012,92(27)：1904
34尤昱中,樊永平.多发性硬化肝肾阴虚与脾肾阳虚患者的质子共振波谱分析及弥散张量成像研究[J].北京中医药大学学报,2011,34(4)：277-281
35张苏明,张励才.N-乙酰天冬氨酸谷氨酸肽酶抑制剂在神经损伤保护中的研究进展[J].中国药理学通报,2013,29(9)：1200-1204
36 Khon O,Filippi M, Freedman MS, et al. Chronic cerebrospinal venous insufficiency and multiple sclerosis[J]. Ann Neurology,2010,67(4):286-290
37段云云,李坤成,刘亚欧,等.应用体素的形态学研究复发缓解型多发性硬化患者的全脑灰质萎缩特[J].中华神经科杂志,2011,44(7)：460-463
38陈少琼,陈世林,胡冰,等.磁共振新技术在多发性硬化的临床应用[J].新医学杂志,2009,40(2)：114-116
39何晓非,周红雨.高级核磁共振成像技术在视神经脊髓炎研究中的应用[J].现代医药卫生杂志,2013,29(16)：2459-2461
40卢彦,于强,王梅,等.多发性硬化患者眼病的临床分析和长期随访[J].中山大学学 报(医学科学版),2009,30(4S)：92-95
41贺丹,杨丽,陈德强,等.多序列磁共振成像在一例多发性硬化诊断中的应用体会[J].脑与神经疾病杂志,2011,19(1)：35-38
42陈璇,李咏梅,欧阳羽,等.不同回波时间氢质子磁共振波谱多体素技术检出多发性硬化病灶和看似正常脑白质区[J].中国医学影像技术,201 1,27(1)：32-36
43李郁欣,初曙光,李振新,等.多发性硬化患者脑灰质损害的MRI表现及扩散张量成像定量研究[J].中华放射学杂志,2008,42(7)：709-713
44周福庆,Chi-Shing Zee,龚洪翰,等.复发一缓解型多发性硬化患者表现正常胼胝体经Hofer's新方案分区的各向异性定量研究[J].实用放射学杂志,2010,26(6)：790-793
45姚青,陈德基,刘克,等.颅脑磁共振弥散张量成像在多发性硬化患者的初步研究[J].广州医学院学报,2011,39(1)：19-23
46周福庆,Chi-Shing Zee,龚洪翰,等.复发-缓解型多发性硬化边缘系统白质纤维束定量DTI改变[J].实用放射学杂志,2010,26(3)：305-308
47樊永平,吴畏.500例多发性硬化患者中医证候研究[J].北京中医药大学学报,2014,37(1)：68-71
48潘玥,李平.李平教授针药并用治疗多发性硬化经验[J].上海针灸杂志,2011,30(12)：859
49赵晖,王蕾,龚慕辛,等.二黄胶囊对实验性自身免疫性脑脊髓炎小鼠细胞免疫的影响[J].首都医科大学学报.2009,30(1)：15-19
50林一聪,董会卿.2010年修订版多发性硬化诊断标准解读[J].中风与神经病杂志,2011,28(8)：764-767
51 Polman CH, Reingold SC, Banwell B, et al. Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria[J]. Ann Neurol,2011,69(2):292-302
52 H. Royden Jones, JR, MD. Netter's Neurology 1st edition[M]. New Jersey:Icon learning systems,2005,29(8):538-557
53 Xiao-Juan Cheng, Li-Zhen Xu. Review of the diagnosis and clinical features of multiple sclerosis in China[J]. Neuroscience,2009,25(1):38-42.
54中华中医药学会.中医内科常见病诊疗指南(西医疾病)[M].中国中医药出版社,2008,249-252
55国家中医药管理局脑病急诊协作组.中风病诊断及疗效评定标准[J].北京：北京中医药大学学报,1996,12(5)：55-57
56李盈,胡学强Th17/Treg失衡在多发性硬化发病和治疗中的意义[J].中国免疫学杂&,2009,6(25):575-576
57 Yulin G, Robert I, Grossman RI. Magnetization-transfer histogram analysis of gray matter in relapsing-remitting multiple sclerosis[J]. AJNR,2011,22(3):470-480
58 Ciccarelli O, Werring DJ, Barker GJ, et al. A study of the mechanisms of normal-appearing white matter damage in multiple sclerosis using diffusion tensor imaging-evidence of Wallerian degeneration[J]. Neurology,2013,250(3):287-292
59汪栋,刘妍,王蕾.髓鞘少突胶质细胞糖蛋白在多发性硬化中的作用[J].医学研究生学报,2010,23(8)：871-875
60黄德晖,吴卫平,蒲传强,等.多发性硬化226例临床分析[J].中国神经免疫学和神经病学杂志,2013,10(3)：152-155
61刘峥,董会卿,贾建平.米托蒽醌在治疗多发性硬化中的应用[J].中华神经科杂志,2012,45(10)：749-751
62 Fanklyn A, Kirstie H, Opstad S.'HMR spectroscopy of brain tumors and masses[J]. NMR Biomedicine,2013,16(9):123-131
63李明智,桂绍高,刘大仁,等.多发性硬化的磁共振波谱研究[J].实用临床医学杂志,2008,9(9)：99-101
64 Michael JF, Fracp AB, Mark JD,et al. Mapping of brain tumor metabolites with proton MR spectroscopic imaging:clinical relevance[J]. Radiology,2012,18(5):675-686
65赵薛旭,常华军,李作汉,等.1H磁共振波谱分析在评价多发性硬化轴索损害中的临床价值[J].中国神经免疫学和神经病学杂志,2007,14(5)：253-255
66杨承志,郑阿娟,徐忠信.磁共振氢波谱分析在多发性硬化研究中应用[J].中国医学影像学杂志,2005,13(1)：50-52
67 Siger-Zajdel M, Selmaj KW. Proton magnetic resonance spectroscopy of norma-lappearing white matter in familial and sporadic multiple sclerosis[J]. Neurology,2005, 252(7):830-832
68 Clarke CE, Lowry M. Systematic review of proton magnetic resonance spectroscopy of the striatum in Parkinsonian syndromes[J]. Neurology,2011,8(6):573-577
69武传华,周建峰,杨涛.1H磁共振波谱在脑多发性硬化诊断中的价值[J].现代诊断与治疗,2005,16(3)：136-139
70周小丰,刘远健.多发性硬化的磁共振扩散张量成像研究[J].医学影像学杂志,2010,20(6)：889-891
71李郁欣,耿道颖.多发性硬化的磁共振弥散张量成像研究[J].医学影像学杂志,2010,20(2)：251-253
72黄薇馨,郑金瓯.多发性硬化患者认知功能损害及核磁共振弥散张量成像研究[J].计算机应用杂志,2013,33(6)：1737-174
73 Kurtzke JF. Rating neurologic impairment in multiple sclerosis:an Expanded Disability Status Scale(EDSS) [M],1983,33:1444-1452
74樊永平,宋丽君,叶明,等.二黄胶囊对实验性自身免疫性脑脊髓炎大鼠中枢神经系统细胞因子和淋巴细胞亚群免疫组化表达的影响[J].中国实验方剂学杂志,2010,16(5)：142-146
75朱文浩,高颖.论多发性硬化与肝肾的关系[J].中国中医急症杂志,2012,21(12)：1918-1919
76郑琦,杨涛,徐大鹏,等.补肾方药防治多发性硬化研究述评[J].辽宁中医药大学学报,2011,13(8)：96-98
77周莉,樊永平,王蕾,等.二黄胶囊对EAE大鼠细胞因子及Th1/Th2平衡的影响.首都医科大学学报,2009,30(1)：20-23
78吴畏,樊永平,胡蕊.多发性硬化及视神经脊髓炎的临床特点和中医证候比较研究[J].北京中医药杂志,2013,32(7)：506-508
79樊永平,周莉,王蕾,等.二黄方对EAE大鼠急性期血浆MCP-1、TNF-α水平的影响[J].北京中医药,2009,28(3)：225-227.
80李康宁,樊永平,陈克龙,等.二黄胶囊对实验性变态反应性脑脊髓炎模型大鼠急性期炎性反应和髓鞘修复的影响[J].首都医科大学学报,2011,32(1)：110-115.
81叶明,樊永平.中药成分与复方防治实验性自身免疫性脑脊髓炎的研究进展[J].北京中医药杂志,2009,28(1)：67-69
82樊永平,宋丽君,叶明,等.左归丸和右归丸对自身免疫性脑脊髓炎大鼠中枢神经系统淋巴细胞亚群免疫组化表达的影响[J].中国中医药信息杂志,2010,17(6)：44-46
83樊永平.寻找中西医脑病之短板,发挥结合医学之优势[J].首都医科大学学报,2009,30(1)：11-14
84郑琦,杨涛,房玲,等.补肾益髓胶囊对实验性自身免疫性脑脊髓炎小鼠大脑内BDNF和NogoA的影响[J].南京中医药大学学报,2013,29(5)：439-444
85周莉,樊永平.二黄方减少多发性硬化轴索损伤和复发的临床研究[J].中国中医药信息杂志,2012,19(8)：14-15
86李菲.中医辨证思维辨证方法与辨证体系[J].辽宁中医杂志,2009,36(2)：213-214
87樊永平,尤昱中,陈克龙,等.261例多发性硬化患者临床特点和中医证候分布[J].首都医科大学学报,2012,33(3)：301-306
88张东友.医学影像学与中医学结合[J].中国中西医结合影像学杂志,2009,7(1)：1-4
89于春水,李坤成.弥散张量成像纤维跟踪技术的研究进展[J].中国医学影像技术,2004,20(3)：477-479
90邝菲,王飞.氢质子磁共振波谱(1H-MRS)技术应用[J].医学影像学杂志,2007,17(8)：871-874
91张海琴,李坤成,于春水,等.磁化传递成像观察多发性硬化大鼠中枢神经系统病灶[J].医学影像学杂志,2011,21(8)：1269-1272
92王德河,李咏梅,吴彤华,等.红细胞生成素水平与多发性硬化合并贫血的相关性[J].中国医学科学院学报,2013,35(1)：84-87
93李勇,管璇,宋兴伟,等.山茱萸总甙对实验性变态性脑脊髓炎大鼠外周一氧化氮的影响[J].浙江中医药大学学报,2012,36(1)：61-63
94王立新,陈绍宏.多发性硬化的中医研究进展[J].广西中医学院学报,2011,14(3)：77-78
95周莉,高颖,邹忆怀,等.详析四诊素材慎思临证技巧—王永炎教授查房实录[J].北京中医药大学学报(中医临床版),2012,19(2)：37-39
96周莉,樊永平.59例多发性硬化患者不同中医证型的免疫学研究[J].中国中西医结合杂志,2007,27(7)：599-601
97郝小波,中西医结合三步法治疗多发性硬化的体会[J].世界中西医结合杂志,2008,3(12)：186-187
98李靖.朱良春医案研读[J].中国实验方剂学杂志,2011,17(3)：238-239
99尚晓琳,高颖,尹岭,等.益肾达络饮对实验性自身免疫性脑脊髓炎MCP-1的影响[J].天津中医药杂志,2006,23(5)：405-407
100陈韫炜.黄芪桂枝五物汤加味治疗多发性硬化30例[J].湖南中医杂志,2006,22(5)：50-51
101王向阳.跟师医案3则[J].中国中医药现代远程教育杂志,2011,9(12)：8-9
102段磊.益气活血化痰汤对多发性硬化临床疗效评价[J].河北医药杂志,2013,35(3)：460-461
103吴彦青,高颖.湿热与多发性硬化症候特点的相关性探析[J].中医研杂志,2011,24(1)：7-9
104吴彦青,高颖,朱陵群,等.实验性自身免疫性脑脊髓炎小鼠中枢神经组织中CD4mRNA对其的影响[J].中国中医急症,2012,21(11)：1760-1762
105孟闯,付菊花,马云枝.马云枝教授治疗多发性硬化经验[J].中国民间疗法杂志,2010,18(12)：10-11
106黄思进.小续命汤临床应用体会[J].中国中医药信息杂志,2012,19(11)：87-88
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |